"antianemic drugs. this classification denotes drugs that treat a reduction in the number of circulating erythrocytes or in the quantity of hemoglobin.. . "
"antianemic drugs. this classification denotes drugs that treat a reduction in the number of circulating erythrocytes or in the quantity of hemoglobin.. magnesium pidolate. this classification denotes an iron supplement which generally arises in the molecular formula c10h12mgn2o6, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier v5pc588n7g, chemically known as magnesium;(2s)-5-oxopyrrolidine-2-carboxylate but generally known as magnesium pidolate, which bears us nih compound identifier 18601084. european medicines agency schedules magnesium pidolate in its extended eudravigilance medicinal product dictionary or xevmpd under index sub03045mig. as of q4 2014, magnesium pidolate remains the us fda preferred term for this commodity. smiles: c1cc(=o)nc1c(=o)[o-].c1cc(=o)nc1c(=o)[o-].[mg+2].. "
"antianemic drugs. this classification denotes drugs that treat a reduction in the number of circulating erythrocytes or in the quantity of hemoglobin.. erythropoietin. this classification denotes a chemotherapy regimen used to treat non-hodgkins lymphoma with the molecular formula c809h1301n229o240s5, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 64fs3bfh5w, more generally known as erythropoietin. european medicines agency schedules erythropoietin in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06575mig. the term erythropoietin is an international non-proprietary name or inn. as of q4 2014, erythropoietin remains the us fda preferred term for this commodity. erythropoietin bears us nlm identifiers umls id c0014822 and nci concept code c20429. smiles: none.. "
"antianemic drugs. this classification denotes drugs that treat a reduction in the number of circulating erythrocytes or in the quantity of hemoglobin.. darbepoetin alfa. this classification denotes a gnas gene with the molecular formula c800h1300n228o24s5, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 15uq94pt4p, more generally known as darbepoetin alfa. european medicines agency schedules darbepoetin alfa in its extended eudravigilance medicinal product dictionary or xevmpd under index sub12486mig. the term darbepoetin alfa is an international non-proprietary name or inn. most nations schedule darbepoetin alfa under hs 30021095 and sitc 54163. as of q4 2014, darbepoetin alfa remains the us fda preferred term for this commodity. darbepoetin alfa bears us nlm identifiers umls id c0937950 and nci concept code c1878. smiles: none.. "
"antianemic drugs. this classification denotes drugs that treat a reduction in the number of circulating erythrocytes or in the quantity of hemoglobin.. epoetin alfa. this classification denotes a chemotherapy regimen used to treat non-hodgkins lymphoma with the molecular formula c809h1301n229o240s5, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 64fs3bfh5w, more generally known as epoetin alfa. european medicines agency schedules epoetin alfa in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06575mig. the term erythropoietin is an international non-proprietary name or inn. epoetin alfa bears us nlm identifiers umls id c0357126 and nci concept code c2695.. "
"antianemic drugs. this classification denotes drugs that treat a reduction in the number of circulating erythrocytes or in the quantity of hemoglobin.. ferric ammonium citrate. this classification denotes a ferric and quaternary ammonium compound with the molecular formula c6h8o7.fe.h3n, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier uvp74ng1c5, chemically known as 1,2,3-propanetricarboxylic acid, 2-hydroxy-, ammonium iron(3+) salt but generally known as ferric ammonium citrate, which bears us nih compound identifier 14457. european medicines agency schedules ferric ammonium citrate in its extended eudravigilance medicinal product dictionary or xevmpd under index sub13834mig. world health organization schedules ferric ammonium citrate in its anatomical therapeutic chemical (atc) classification. most nations schedule ferric ammonium citrate under hs 28444030 and sitc 52519. as of q4 2014, ferric ammonium citrate remains the us fda preferred term for this commodity. smiles: c(c(=o)[o-])c(cc(=o)[o-])(c(=o)[o-])o.n.[fe+3].. "
"antianemic drugs. this classification denotes drugs that treat a reduction in the number of circulating erythrocytes or in the quantity of hemoglobin.. heme iron polypeptide. this classification denotes an iron supplement, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 31vdo12cjy. as of q4 2014, heme iron polypeptide remains the us fda preferred term for this commodity.. "
"antianemic drugs. this classification denotes drugs that treat a reduction in the number of circulating erythrocytes or in the quantity of hemoglobin.. carbonyl iron. this classification denotes a complex of iron atoms chelated with carbonyl ions, and which generally arises in the molecular formula c5feo5, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 6wq62taq6z. european medicines agency schedules carbonyl iron in its extended eudravigilance medicinal product dictionary or xevmpd under index sub14266mig. smiles: [c-]#[o+].[c-]#[o+].[c-]#[o+].[c-]#[o+].[c-]#[o+].[fe].. "
"antianemic drugs. this classification denotes drugs that treat a reduction in the number of circulating erythrocytes or in the quantity of hemoglobin.. hematin or hemin. this classification denotes an iron supplement which generally arises in the molecular form c34h32n4o4.fe.ho, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 0wp180g15g. smiles: cc1=c(c2=cc3=c(c(=c([n-]3)c=c4c(=c(c(=n4)c=c5c(=c(c(=n5)c=c1[n-]2)c=c)c)c=c)c)c)ccc(=o)o)ccc(=o)o.o.[fe+2].. "
"antianemic drugs. this classification denotes drugs that treat a reduction in the number of circulating erythrocytes or in the quantity of hemoglobin.. sodium ferric gluconate. this classification denotes a nutritional supplement, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier cc9149u2qx. european medicines agency schedules sodium ferric gluconate complex in its extended eudravigilance medicinal product dictionary or xevmpd under index sub20743. ferric na gluconate generally arises in the molecular formula c6h11o7.fe.na. the term ferric na gluconate is a united states adopted name designation. smiles: [fe].[na].oc(c(o)c(o)c(=o)o)c(o)co.. "
"antianemic drugs. this classification denotes drugs that treat a reduction in the number of circulating erythrocytes or in the quantity of hemoglobin.. plerixafor. this classification denotes a chemokine receptor antagonist and antiviral agent, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier s915p5499n. european medicines agency schedules plerixafor in its extended eudravigilance medicinal product dictionary or xevmpd under index sub28849. plerixafor generally arises in the molecular formula c28h54n8. the term plerixafor is an international non-proprietary name or inn (see who inn reference publication, volume 20, no. 1, 2006, list 55.) plerixafor is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule plerixafor under hs 29339990 and sitc 51577. as of q4 2014, plerixafor remains the us fda preferred term for this commodity. plerixafor bears us nlm identifiers umls id c0257001 and nci concept code c1777. smiles: c1cnccncccn(ccnc1)cc2=cc=c(c=c2)cn3cccnccncccncc3.. "
"antianemic drugs. this classification denotes drugs that treat a reduction in the number of circulating erythrocytes or in the quantity of hemoglobin.. sodium feredetate. this classification denotes a nutritional supplement with the molecular formula c10h12n2o8.fe.na, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 403j23emfa, chemically known as sodium (n,n,n,n-ethylenediaminetetraacetato)ferrate(1-) but generally known as sodium feredetate, which bears us nih compound identifier 27461. european medicines agency schedules sodium feredetate in its extended eudravigilance medicinal product dictionary or xevmpd under index sub10560mig. world health organization schedules sodium feredetate in its anatomical therapeutic chemical (atc) classification. most nations schedule sodium feredetate under hs 29224995 and sitc 51465. as of q4 2014, sodium feredetate remains the us fda preferred term for this commodity. sodium feredetate bears us nlm identifiers umls id c0357084 and nci concept code c76827. smiles: c(cn(cc(=o)o)cc(=o)[o-])n(cc(=o)o)cc(=o)[o-].[na+].[fe+5].. "
"antianemic drugs. this classification denotes drugs that treat a reduction in the number of circulating erythrocytes or in the quantity of hemoglobin.. iron polysaccharide. this classification denotes an iron supplement. european medicines agency schedules iron polysaccharide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub14951mig. iron polysaccharide bears us nlm identifiers umls id c0722705 and nci concept code c89826.. "
"antianemic drugs. this classification denotes drugs that treat a reduction in the number of circulating erythrocytes or in the quantity of hemoglobin.. ferumoxytol. an iron replacement product indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (ckd).. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. . "
"anticoagulants. this classification denotes agents that prevent blood clotting.. heparin. this classification denotes a low molecular weight heparin with the molecular formula (c14h18no11)n.2(c12h16no13s)n.3ho3s, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 7uq7x4y489. european medicines agency schedules heparin in its extended eudravigilance medicinal product dictionary or xevmpd under index sub02475mig. the term heparin is a u.s. fda designation. heparin is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule heparin under hs 30019000 and sitc 54162. as of q4 2014, heparin remains the us fda preferred term for this commodity. heparin bears us nlm identifiers umls id c0019134 and nci concept code c539. smiles: cc(=o)nc1c(c(c(oc1o)cos(=o)(=o)o)oc2c(c(c(c(o2)c(=o)o)oc3c(c(c(c(o3)co)oc4c(c(c(c(o4)c(=o)o)o)o)os(=o)(=o)o)os(=o)(=o)o)ns(=o)(=o)o)o)os(=o)(=o)o)o.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. warfarin. this classification denotes a coumarin compound and anticoagulant agent with the molecular formula c19h16o4, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 5q7zvv76ei, chemically known as 2h-1-benzopyran-2-one, 4-hydroxy-3-(3-oxo-1-phenylbutyl)-, & salts, when present at concentrations greater than 0.3% but generally known as warfarin, which bears us nih compound identifier 6691. european medicines agency schedules warfarin in its extended eudravigilance medicinal product dictionary or xevmpd under index sub00090mig. the term warfarin is an international non-proprietary name. world health organization schedules warfarin in its anatomical therapeutic chemical (atc) classification. warfarin is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, warfarin remains the us fda preferred term for this commodity. warfarin bears us nlm identifiers umls id c0043031 and nci concept code c945. smiles: o1c(o)c(c(cc(=o)c)c2ccccc2)c(=o)c2c1cccc2.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. sodium citrate. this classification denotes an electrolyte replacement agent and anticoagulant agent, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 1q73q2julr. european medicines agency schedules sodium citrate in its extended eudravigilance medicinal product dictionary or xevmpd under index sub12582mig. sodium citrate generally arises in the molecular formula c6h5na3o7. the term sodium citrate is a u.s. pharmacopeial convention designation. as of q4 2014, sodium citrate remains the us fda preferred term for this commodity. sodium citrate bears us nlm identifiers umls id c0142825 and nci concept code c62075. smiles: c(c(=o)[o-])c(cc(=o)[o-])(c(=o)[o-])o.[na+].[na+].[na+].. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. sodium apolate. this classification denotes an anticoagulant agent and a alkyl sulfonate, phosphogluconate dehydrogenase antagonists and inhibitor, polyvinyl, polyethylene, and sulfonic acid with the molecular formula c2h3nao3s, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 9461405d9f, chemically known as sodium;ethenesulfonate but generally known as sodium apolate, which bears us nih compound identifier 3270262. european medicines agency schedules sodium apolate in its extended eudravigilance medicinal product dictionary or xevmpd under index sub05545mig. the term sodium apolate is an international non-proprietary name or inn (see who inn reference publication, vol 20 1966, list 6). most nations schedule sodium apolate under hs 39019090 and sitc 57190. smiles: c=cs(=o)(=o)[o-].[na+]. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. enoxaparin. this classification denotes a low molecular weight heparin, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier e47c0nf7lv. european medicines agency schedules enoxaparin in its extended eudravigilance medicinal product dictionary or xevmpd under index sub21316. enoxaparin generally arises in the molecular formula (c14h18no11)n.c14h18no11.c12h17no12s.(c12h16no13s)n.c12h15no13s.na.h.5ho3s. the term enoxaparin is an international non-proprietary name or inn (see who inn reference publication, volume 39, no. 5, 1985, list 25.) enoxaparin is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, enoxaparin remains the us fda preferred term for this commodity. enoxaparin bears us nlm identifiers umls id c0206460 and nci concept code c1452. smiles: cc(=o)nc1c(c(c(oc1o)cos(=o)(=o)o)oc2c(c(c(c(o2)c(=o)o)oc3c(c(c(c(o3)co)oc4c(c(c(c(o4)c(=o)o)o)o)os(=o)(=o)o)os(=o)(=o)o)ns(=o)(=o)o)o)os(=o)(=o)o)o.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. lepirudin. this classification denotes an anticoagulant agent with the molecular formula c287h440n80o111s6, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier y43gf64r34, chemically known as hirudin (hirudo medicinalis isoform hv1), 63-desulfo- but generally known as lepirudin, which bears us nih compound identifier 16129703. european medicines agency schedules lepirudin in its extended eudravigilance medicinal product dictionary or xevmpd under index sub08435mig. the term lepirudin is an international non-proprietary name or inn (see who inn reference publication, volume 10, no. 3, 1996, list 36). world health organization schedules lepirudin in its anatomical therapeutic chemical (atc) classification. most nations schedule lepirudin under hs 29349990 and sitc 51579. as of q4 2014, lepirudin remains the us fda preferred term for this commodity. lepirudin bears us nlm identifiers umls id c0772394 and nci concept code c1839. smiles: s1scc2nc(=o)c(nc(=o)c(nc(=o)c(nc(=o)cnc(=o)c(nc(=o)c(nc(=o)c(nc(=o)c3nc(=o)c(nc(=o)c(nc(=o)c(nc(=o)cnc(=o)c(nc(=o)c(nc(=o)c(nc(=o)c(nc(=o)c(nc(=o)c(nc(=o)c(nc(=o)c(nc(=o)c(n)c(c)c)c(c)c)cc4ccc(o)cc4)c(o)c)cc(=o)o)cssc3)c(o)c)ccc(=o)o)co)ccc(=o)n)cc(=o)n)c.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. desirudin. this classification denotes an anticoagulant agent with the molecular formula c287h440n80o110s6, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier u0jz726775, chemically known as hirudin (hirudo medicinalis isoform hv1), 63-desulfo- but generally known as desirudin, which bears us nih compound identifier 16129703. european medicines agency schedules desirudin in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06996mig. the term desirudin is an international non-proprietary name. world health organization schedules desirudin in its anatomical therapeutic chemical (atc) classification. desirudin is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule desirudin under hs 30019098 and sitc 54162. as of q4 2014, desirudin remains the us fda preferred term for this commodity. desirudin bears us nlm identifiers umls id c1259412 and nci concept code c47473. smiles: s1scc2nc(=o)c(nc(=o)c(nc(=o)c(nc(=o)cnc(=o)c(nc(=o)c(nc(=o)c(nc(=o)c3nc(=o)c(nc(=o)c(nc(=o)c(nc(=o)cnc(=o)c(nc(=o)c(nc(=o)c(nc(=o)c(nc(=o)c(nc(=o)c(nc(=o)c(nc(=o)c(nc(=o)c(n)c(c)c)c(c)c)cc4ccc(o)cc4)c(o)c)cc(=o)o)cssc3)c(o)c)ccc(=o)o)co)ccc(=o)n)cc(=o)n)c.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. ardeparin. this classification denotes a low molecular weight heparin, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier n3927d01pb. european medicines agency schedules ardeparin sodium in its extended eudravigilance medicinal product dictionary or xevmpd under index sub00574mig. ardeparin sodium generally arises in the molecular formula (c14h18no11)n.2(c12h15no13s)n.3na.3o3s. the term ardeparin sodium is an international non-proprietary name or inn (see who inn reference publication, volume 7, no3, 1993, list 33.) as of q4 2014, ardeparin remains the us fda preferred term for this commodity. smiles: c(c1c(c(c(c(o1)o)ns(=o)(=o)[o-])o)oc2c(c(c(c(o2)c(=o)[o-])o)o)os(=o)(=o)[o-])os(=o)(=o)[o-].. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. dalteparin. this classification denotes a low molecular weight heparin with the molecular formula (c14h18no11)n.2(c12h16no13s)n.3ho3s, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier s79o08v79f. european medicines agency schedules dalteparin in its extended eudravigilance medicinal product dictionary or xevmpd under index sub02475mig. dalteparin is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, dalteparin remains the us fda preferred term for this commodity. dalteparin bears us nlm identifiers umls id c0206461 and nci concept code c1453. smiles: cc(=o)nc1c(c(c(oc1o)cos(=o)(=o)o)oc2c(c(c(c(o2)c(=o)o)oc3c(c(c(c(o3)co)oc4c(c(c(c(o4)c(=o)o)o)o)os(=o)(=o)o)os(=o)(=o)o)ns(=o)(=o)o)o)os(=o)(=o)o)o.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. dicoumarol or dicumarol. this classification denotes a coumarin compound and anticoagulant agent with the molecular formula c19h12o6, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 7qid3e7bg7, chemically known as 4,4-dihydroxy-3,3-methylene bis coumarin but more generally known as dicoumarol, which bears us nih compound identifier 653. european medicines agency schedules dicoumarol in its extended eudravigilance medicinal product dictionary or xevmpd under index sub07101mig. the term dicoumarol is an international non-proprietary name or inn (see world health organization inn reference publication, volume 25 , no. 10 1971, list 11). world health organization schedules dicoumarol in its anatomical therapeutic chemical (atc) classification. dicoumarol is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. dicumarol bears us nlm identifiers umls id c0005640 and nci concept code c310. smiles: o1c(o)c(cc2c(=o)c3c(oc2o)cccc3)c(=o)c2c1cccc2.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. anisindione. this classification denotes an anticoagulant agent with the molecular formula c16h12o3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier s747t1eraj, chemically known as 1,3-indanedione, 2-(4-methoxyphenyl)- but generally known as anisindione, which bears us nih compound identifier 2197. european medicines agency schedules anisindione in its extended eudravigilance medicinal product dictionary or xevmpd under index sub05520mig. the term anisindione is an international non-proprietary name or inn (see who inn reference publication, volume 16, no. 3 1962, list 4). anisindione is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule anisindione under hs 29145000 and sitc 51629. as of q4 2014, anisindione remains the us fda preferred term for this commodity. anisindione bears us nlm identifiers umls id c0051919 and nci concept code c47398. smiles: o=c1c(c(=o)c2c1cccc2)c1ccc(oc)cc1.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. fondaparinux. this classification denotes an anticoagulant agent, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier j177fow5jl. european medicines agency schedules fondaparinux in its extended eudravigilance medicinal product dictionary or xevmpd under index sub25907. fondaparinux generally arises in the molecular formula c31h43n3na10o49s8. the term fondaparinux is a hazardous substances data bank designation. as of q4 2014, fondaparinux remains the us fda preferred term for this commodity. fondaparinux bears us nlm identifiers umls id c0701492 and nci concept code c73142. smiles: s(=o)(=o)(o)nc1c(os(=o)(=o)o)c(oc2oc(c(oc3oc(c(o)c(o)c3ns(=o)(=o)o)cos(=o)(=o)o)c(o)c2o)c(=o)o)c(oc1oc1c(o)c(os(=o)(=o)o)c(oc1c(=o)o)oc1c(o)c(ns(=o)(=o)o)c(oc1cos(=o)(=o)o)oc)cos(=o)(=o)o.[na].[na].[na].[na].[na].[na].[na].[na].[na].[na].. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. anticoagulant citrate phosphate dextrose solution. this classification denotes an anticoagulant agent with the molecular formula c12h23o17p, chemically known as 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid but generally known as anticoagulant citrate phosphate dextrose solution, which bears us nih compound identifier 123830. european medicines agency schedules anticoagulant citrate phosphate dextrose solution in its extended eudravigilance medicinal product dictionary or xevmpd under index sub25621 and sub25620. smiles:c(c(c(c(c(c=o)o)o)o)o)o.c(c(=o)o)c(cc(=o)o)(c(=o)o)o.op(=o)(o)o.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. beraprost. this classification denotes a prostaglandin analogue with the molecular formula c24h30o5, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 35e3njj4o6, chemically known as 2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2,3,3a,8b-tetrahydro-1h-cyclopenta(b)benzofuran-5-butanoic acid but generally known as beraprost, which bears us nih compound identifier 5282428. beraprost most often comes in base and sodium forms. european medicines agency schedules beraprost in its extended eudravigilance medicinal product dictionary or xevmpd under index sub05779mig. world health organization schedules beraprost in its anatomical therapeutic chemical (atc) classification. beraprost is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule beraprost under hs 29375000 and sitc 54156. as of q4 2014, beraprost remains the us fda preferred term for this commodity. beraprost bears us nlm identifiers umls id c0053336 and nci concept code c76896. smiles: o1c2c(c(c(o)c2)/c=c/c(o)c(cc#cc)c)c2c1c(ccc2)cccc(=o)o.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. acenocoumarol. this classification denotes an anticoagulant agent with the molecular formula c19h15no6, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier i6wp63u32h, chemically known as 2h-1-benzopyran-2-one, 4-hydroxy-3-(1-(4-nitrophenyl)-3-oxobutyl)- but generally known as acenocoumarol, which bears us nih compound identifier 9052. european medicines agency schedules acenocoumarol in its extended eudravigilance medicinal product dictionary or xevmpd under index sub05211mig. the term acenocoumarol is an international non-proprietary name or inn (see who inn reference publication, volume 13, no. 12, 1959, list 3). world health organization schedules acenocoumarol in its anatomical therapeutic chemical (atc) classification. acenocoumarol is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, acenocoumarol remains the us fda preferred term for this commodity. acenocoumarol bears us nlm identifiers umls id c0000956 and nci concept code c75152. smiles: o1c(o)c(c(cc(=o)c)c2ccc([n](=o)o)cc2)c(=o)c2c1cccc2.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. anagrelide hydrochloride. this classification denotes an antiplatelet agent with the molecular formula c10h7cl2n3o.clh, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier vns4435g39, chemically known as 6,7-dichloro-1,5-dihydroimidazo(2,1-b)-quinazolin-2(3h)-one monohydrochloride but generally known as anagrelide hydrochloride, which bears us nih compound identifier 42786. european medicines agency schedules anagrelide hydrochloride in its extended eudravigilance medicinal product dictionary or xevmpd under index sub00523mig. most nations schedule anagrelide hydrochloride under hs 29335995 and sitc 51576. as of q4 2014, anagrelide hydrochloride remains the us fda preferred term for this commodity. anagrelide hydrochloride bears us nlm identifiers umls id c0771907 and nci concept code c28826. smiles: c1c2=c(c=cc(=c2cl)cl)nc3=nc(=o)cn31.cl.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. apixaban. this classification denotes an anticoagulant agent, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 3z9y7uwc1j. european medicines agency schedules apixaban in its extended eudravigilance medicinal product dictionary or xevmpd under index sub25425. apixaban generally arises in the molecular formula c25h25n5o4. the term apixaban is an international non-proprietary name or inn (see who inn reference publication, volume 20, no. 1, 2006, list 55.) apixaban is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule apixaban under hs 29337900 and sitc 51561. as of q4 2014, apixaban remains the us fda preferred term for this commodity. apixaban bears us nlm identifiers umls id c1831808 and nci concept code c61308. smiles: o=c1n(ccc2c1n(nc2c(=o)n)c1ccc(oc)cc1)c1ccc(n2ccccc2=o)cc1.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. aprosulate. this classification denotes an anticoagulant agent with the molecular formula c27h34n2o70s16, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier x94b38cqom, chemically known as n,n-trimethylenebis(actobionamide) hexadecakis sulfate (ester) but generally known as aprosulate, which bears us nih compound identifier 72125. european medicines agency schedules aprosulate in its extended eudravigilance medicinal product dictionary or xevmpd under index sub05545mig. the term aprosulate is an international non-proprietary name or inn (see who inn reference publication, volume 5, no. 3 1991, list 31). as of q4 2014, aprosulate remains the us fda preferred term for this commodity. aprosulate bears us nlm identifiers umls id c0103894 and nci concept code c87428. smiles: c(cnc(=o)c(c(c(c(cos(=o)(=o)[o-])os(=o)(=o)[o-])oc1c(c(c(c(o1)cos(=o)(=o)[o-])os(=o)(=o)[o-])os(=o)(=o)[o-])os(=o)(=o)[o-])os(=o)(=o)[o-])os(=o)(=o)[o-])cnc(=o)c(c(c(c(cos(=o)(=o)[o-])os(=o)(=o)[o-])oc2c(c(c(c(o2)cos(=o)(=o)[o-])os(=o)(=o)[o-])os(=o)(=o)[o-])os(=o)(=o)[o-])os(=o)(=o)[o-])os(=o)(=o)[o-].[na+].[na+].[na+].[na+].[na+].[na+].[na+].[na+].[na+].[na+].[na+].[na+].[na+].[na+].[na+].[na+].. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. beciparcil. this classification denotes an anticoagulant agent, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier k90zor23p1. european medicines agency schedules beciparcil in its extended eudravigilance medicinal product dictionary or xevmpd under index sub05674mig. beciparcil generally arises in the molecular formula c12h13no3s2. the term beciparcil is an international non-proprietary name or inn (see who inn reference publication, volume 8 no. 3 1994, list 34.) beciparcil is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule beciparcil under hs 29349990 and sitc 51579. as of q4 2014, beciparcil remains the us fda preferred term for this commodity. beciparcil bears us nlm identifiers umls id c0761070 and nci concept code c73225. smiles: c1c(c(c(c(s1)sc2=cc=c(c=c2)c#n)o)o)o.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. dabigatran etexilate mesilate. this classification denotes an anticoagulant agent, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier sc7nuw5iit. the european medicines agency schedules dabigatran etexilate mesilate in its extended eudravigilance medicinal product dictionary or xevmpd under index sub27581. dabigatran etexilate mesilate generally arises in the molecular formula c34h41n7o5.ch4o3s. the term dabigatran etexilate mesilate is a european medicines agency european public assessment report system designation. smiles: ccccccoc(=o)n=c(c1=cc=c(c=c1)ncc2=nc3=c(n2c)c=cc(=c3)c(=o)n(ccc(=o)occ)c4=cc=cc=n4)n.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. bivalirudin. this classification denotes an anticoagulant agent with the molecular formula c98h138n24o33, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier tn9bex005g, chemically known as l-leucine, d-phenylalanyl-l-prolyl-l-arginyl-l-prolylglycylglycylglycylglycyl-l-asparaginylglycyl-l-alpha-aspartyl-l-phenylalanyl-l-alpha-glutamyl-l-alpha-glutamyl-l-isoleucyl-l-prolyl-l-alpha-glutamyl-l-alpha-glutamyl-l-tyrosyl- but generally known as bivalirudin, which bears us nih compound identifier 16129704. european medicines agency schedules bivalirudin in its extended eudravigilance medicinal product dictionary or xevmpd under index sub05862mig. the term bivalirudin is an international non-proprietary name or inn (see who inn reference publication, volume 9, no. 3, 1995, list 35). world health organization schedules bivalirudin in its anatomical therapeutic chemical (atc) classification. bivalirudin is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule bivalirudin under hs 29339990 and sitc 51577. as of q4 2014, bivalirudin remains the us fda preferred term for this commodity. bivalirudin bears us nlm identifiers umls id c0168273 and nci concept code c47415. smiles: o=c(n1c(ccc1)c(=o)nc(ccc(=o)o)c(=o)nc(ccc(=o)o)c(=o)nc(cc1ccc(o)cc1)c(=o)nc(cc(c)c)c(=o)o)c(nc(=o)c(nc(=o)c(nc(=o)c(nc(=o)c(nc(=o)cnc(=o)c(nc(=o)cnc(=o)cnc(=o)cnc(=o)cnc(=o)c1n(ccc1)c(=o)c(nc(=o)c1n(ccc1)c(=o)c(n)cc1ccccc1)cccnc(=n)n)cc(=o)n)cc(=o)o)cc1cc.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. camonagrel. this classification denotes an antiplatelet agent, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier xm930m133o. european medicines agency schedules camonagrel in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06065mig. camonagrel generally arises in the molecular formula c15h16n2o3. the term camonagrel is an international non-proprietary name or inn (see who inn reference publication, volume 4, no. 3 1990, list 30.) most nations schedule camonagrel under hs 29332990 and sitc 51573. as of q4 2014, camonagrel remains the us fda preferred term for this commodity. camonagrel bears us nlm identifiers umls id c0534183 and nci concept code c76006. smiles: o(c1cc2ccc(c2cc1)c(=o)o)ccn1ccnc1.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. cangrelor. this classification denotes an antiplatelet agent, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 6aq1y404u7. european medicines agency schedules cangrelor in its extended eudravigilance medicinal product dictionary or xevmpd under index sub26448. cangrelor generally arises in the molecular formula c17h25cl2f3n5o12p3s2. the term cangrelor is an international non-proprietary name or inn (see who inn reference publication, volume 14, no. 3, 2000, list 44.) most nations schedule cangrelor under hs 29349990 and sitc 51579. as of q4 2014, cangrelor remains the us fda preferred term for this commodity. cangrelor bears us nlm identifiers umls id c1121991 and nci concept code c76395. smiles: clc(cl)(p(=o)(op(=o)(occ1oc(n2c3nc(sccc(f)(f)f)nc(nccsc)c3nc2)c(o)c1o)o)o)p(=o)(o)o.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. citric acid. this classification denotes a carboxylic acid with the molecular formula c6h8o7.h2o, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 2968phw8qp. european medicines agency schedules citric acid in its extended eudravigilance medicinal product dictionary or xevmpd under index sub12482mig. the term citric acid monohydrate is a u.s. fda designation. smiles: oc(cc(=o)o)(cc(=o)o)c(=o)o.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. clopidogrel. this classification denotes a thienopyridine antiplatelet agent with the molecular formula c16h16clno2s, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier a74586sno7, chemically known as thieno(3,2-c)pyridine-5(4h)-acetic acid, alpha-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (s)- but generally known as clopidogrel, which bears us nih compound identifier 60606. european medicines agency schedules clopidogrel in its extended eudravigilance medicinal product dictionary or xevmpd under index sub13395mig. world health organization schedules clopidogrel in its anatomical therapeutic chemical (atc) classification. clopidogrel is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule clopidogrel under hs 29349990 and sitc 51579. as of q4 2014, clopidogrel remains the us fda preferred term for this commodity. clopidogrel bears us nlm identifiers umls id c0070166 and nci concept code c61686. smiles: clc1c(c(n2ccc3sccc3c2)c(=o)oc)cccc1.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. clorindione. this classification denotes an anticoagulant agent with the molecular formula c15h9clo2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 541c7ws64r, chemically known as 1,3-indandione, 2-(p-chlorophenyl)- but generally known as clorindione, which bears us nih compound identifier 70846. european medicines agency schedules clorindione in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06760mig. the term clorindione is an international non-proprietary name or inn (see who inn reference publication, volume 19 1975, list 5). world health organization schedules clorindione in its anatomical therapeutic chemical (atc) classification. clorindione is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule clorindione under hs 29147000 and sitc 51629. as of q4 2014, clorindione remains the us fda preferred term for this commodity. clorindione bears us nlm identifiers umls id c0055939 and nci concept code c81463. smiles: clc1ccc(c2c(=o)c3c(c2=o)cccc3)cc1.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. dabigatran. this classification denotes an anticoagulant agent, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier i0vm4m70gc. european medicines agency schedules dabigatran in its extended eudravigilance medicinal product dictionary or xevmpd under index sub25417. dabigatran generally arises in the molecular formula c25h25n7o3. the term dabigatran is an international non-proprietary name or inn (see who inn reference publication, volume 15 no. 3-4, 2001, list 46.) most nations schedule dabigatran under hs 29333999 and sitc 51574. as of q4 2014, dabigatran remains the us fda preferred term for this commodity. dabigatran bears us nlm identifiers umls id c2348066 and nci concept code c73224. smiles: o=c(n(ccc(=o)o)c1ncccc1)c1cc2nc(n(c2cc1)c)cnc1ccc(cc1)c(=n)n.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. diarbarone. this classification denotes an anticoagulant agent, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier il298686u0. european medicines agency schedules diarbarone in its extended eudravigilance medicinal product dictionary or xevmpd under index sub07066mig. diarbarone generally arises in the molecular formula c16h20n2o4. the term diarbarone is an international non-proprietary name or inn. diarbarone is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, diarbarone remains the us fda preferred term for this commodity. diarbarone bears us nlm identifiers umls id c2699622 and nci concept code c77993. smiles: o1c2c(c(=o)c(c(=o)nccn(cc)cc)c1o)cccc2.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. diphacinone or diphenadione. this classification denotes an anticoagulant agent with the molecular formula c23h16o3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 54ca01c6jx, chemically known as 1,3-indandione, 2-(diphenylacetyl)- (8ci) but generally known as diphacinone, which bears us nih compound identifier 6719. european medicines agency schedules diphenadione in its extended eudravigilance medicinal product dictionary or xevmpd under index sub07209mig. the term diphacinone is an international non-proprietary name. world health organization schedules diphacinone in its anatomical therapeutic chemical (atc) classification. diphacinone or diphenadione bears us nlm identifiers umls id c0058366 and nci concept code c75156. smiles: c1=cc=c(c=c1)c(c2=cc=cc=c2)c(=o)c3c(=o)c4=cc=cc=c4c3=o.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. ditazol or ditazole. this classification denotes an antiplatelet agent with the molecular formula c19h20n2o3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier h2bqi5z8ft, chemically known as 4,5-diphenyl-2-bis(2-hydroxyethyl)-aminoxazol but generally known as ditazol, which bears us nih compound identifier 29088. european medicines agency schedules ditazole in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06328mig. the term ditazole is an international non-proprietary name or inn (see who inn reference publication, volume 23, no. 10 1969, list 9). world health organization schedules ditazol in its anatomical therapeutic chemical (atc) classification. ditazol or ditazole bears us nlm identifiers umls id c0012777 and nci concept code c65442. smiles: c1=cc=c(c=c1)c2=c(oc(=n2)n(cco)cco)c3=cc=cc=c3.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. ecraprost. this classification denotes an antiplatelet agent with the molecular formula c28h48o6, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier q2xm6vr8do, chemically known as prosta-8,13-dien-1-oic acid, 11,15-dihydroxy-9-(1-oxobutoxy)-, butyl ester, (11 alpha, 13e,15s)- but generally known as ecraprost, which bears us nih compound identifier 6441614. the term ecraprost is an international non-proprietary name or inn (see who inn reference publication, volume 15 no. 1, 2001, list 45). most nations schedule ecraprost under hs 29375000 and sitc 54156. as of q4 2014, ecraprost remains the us fda preferred term for this commodity. ecraprost bears us nlm identifiers umls id c0671097 and nci concept code c76397. smiles: cccccc(c=cc1c(cc(=c1ccccccc(=o)occcc)oc(=o)ccc)o)o.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. efegatran. this classification denotes a protease inhibitor and anticoagulant agent with the molecular formula c21h32n6o3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier, vt0vk2474k chemically known as l-prolinamide, n-methyl-d-phenylalanyl-n-(4-((aminoiminomethyl)amino)-1-formylbutyl)-, (s)- but generally known as efegatran, which bears us nih compound identifier 122267. european medicines agency schedules efegatran in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06464mig. the term efegatran is an international non-proprietary name or inn (see who inn reference publication, volume 9, no. 3, 1995, list 35). most nations schedule efegatran under hs 29339990 and sitc 51577. as of q4 2014, efegatran remains the us fda preferred term for this commodity. efegatran bears us nlm identifiers umls id c0286590 and nci concept code c72749. smiles: cnc(cc1=cc=cc=c1)c(=o)n2cccc2c(=o)nc(cccn=c(n)n)c=o.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. etabenzarone. this classification denotes an anticoagulant agent with the molecular formula c23h27no3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier da25635w9d, chemically known as methanone, (4-(2-(diethylamino)ethoxy)phenyl)(2-ethyl-3-benzofuranyl)- (9ci) but generally known as etabenzarone, which bears us nih compound identifier 27444. european medicines agency schedules etabenzarone in its extended eudravigilance medicinal product dictionary or xevmpd under index sub07253mig. the term etabenzarone is an international non-proprietary name or inn (see who inn reference publication, volume 21 no. 12 1967, list 7). etabenzarone is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule etabenzarone under hs 29329985 and sitc 51569. as of q4 2014, etabenzarone remains the us fda preferred term for this commodity. etabenzarone bears us nlm identifiers umls id c1880559 and nci concept code c65546. smiles: o1c(c(c2c1cccc2)c(=o)c1ccc(occn(cc)cc)cc1)cc.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. ethyl biscoumacetate. this classification denotes an anticoagulant agent with the molecular formula c22h16o8, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 08kl644731, chemically known as 3,3-(carboxymethylene)bis(4-hydroxycoumarin) ethyl ester but generally known as ethyl biscoumacetate, which bears us nih compound identifier 11047. european medicines agency schedules ethyl biscoumacetate in its extended eudravigilance medicinal product dictionary or xevmpd under index sub07285mig. the term ethyl biscoumacetate is an international non-proprietary name. world health organization schedules ethyl biscoumacetate in its anatomical therapeutic chemical (atc) classification. as of q4 2014, ethyl biscoumacetate remains the us fda preferred term for this commodity. ethyl biscoumacetate bears us nlm identifiers umls id c0015056 and nci concept code c75157. smiles: o1c(o)c(c(c2c(=o)c3c(oc2o)cccc3)c(=o)occ)c(=o)c2c1cccc2.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. fradafiban. this classification denotes an anticoagulant agent with the molecular formula c20h21n3o4, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier dq0h2b8ykn, chemically known as (3s,5s)-5-(((4-amidino-4-biphenylyl)oxy)methyl)-2-oxo-3-pyrrolidineacetic acid but generally known as fradafiban, which bears us nih compound identifier 66000. european medicines agency schedules fradafiban in its extended eudravigilance medicinal product dictionary or xevmpd under index sub07813mig. the term fradafiban is an international non-proprietary name or inn (see who inn reference publication, volume 9, no. 3, 1995, list 35). fradafiban is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule fradafiban under hs 29337900 and sitc 51561. as of q4 2014, fradafiban remains the us fda preferred term for this commodity. fradafiban bears us nlm identifiers umls id c0665276 and nci concept code c65769. smiles: o(cc1nc(=o)c(c1)cc(=o)o)c1ccc(cc1)c1ccc(cc1)c(=n)n.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. gabexate. this classification denotes a protease inhibitor and anticoagulant agent with the molecular formula c16h23n3o4, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 4v7m9137x9, chemically known as benzoic acid, 4-((6-((aminoiminomethyl)amino)-1-oxohexyl)oxy)-, ethyl ester but generally known as gabexate, which bears us nih compound identifier 3447. european medicines agency schedules gabexate in its extended eudravigilance medicinal product dictionary or xevmpd under index sub07858mig. the term gabexate is an international non-proprietary name or inn (see who inn reference publication, volume 30, no. 10 1976, list 16). gabexate is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule gabexate under hs 29252900 and sitc 51482. as of q4 2014, gabexate remains the us fda preferred term for this commodity. gabexate bears us nlm identifiers umls id c0085231 and nci concept code c76960. smiles: o(c(=o)ccccc/n=c(/n)n)c1ccc(cc1)c(=o)occ.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. nadroparin. this classification denotes a low molecular weight heparin with the molecular formula (c14h18no11)n.2(c12h16no13s)n.3ho3s, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 1k5kdi46kz. european medicines agency schedules nadroparin in its extended eudravigilance medicinal product dictionary or xevmpd under index sub03371mig. as of q4 2014, nadroparin remains the us fda preferred term for this commodity. smiles: c(c1c(c(c(c(o1)o)ns(=o)(=o)[o-])o)oc2c(c(c(c(o2)c(=o)[o-])o)o)os(=o)(=o)[o-])os(=o)(=o)[o-].. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. iloprost. this classification denotes a prostaglandin analogue and chemopreventive agent, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier jed5k35ygl. european medicines agency schedules iloprost in its extended eudravigilance medicinal product dictionary or xevmpd under index sub08136mig. iloprost generally arises in the molecular formula c22h32o4. the term iloprost is an international non-proprietary name or inn (see who inn reference publication, volume 37, no. 6, 1983, list 23.) iloprost is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule iloprost under hs 29375000 and sitc 54156. as of q4 2014, iloprost remains the us fda preferred term for this commodity. iloprost bears us nlm identifiers umls id c0079594 and nci concept code c48397. smiles: cc#ccc(c)c(c=cc1c(cc2c1cc(=ccccc(=o)o)c2)o)o.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. indobufen. this classification denotes a nonsteroidal antiinflammatory drug with the molecular formula c18h17no3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 6t9949g4lz, chemically known as 4-(1,3-dihydro-1-oxo-2h-isoindol-2-yl)-alpha-ethylbenzeneacetic acid but generally known as indobufen, which bears us nih compound identifier 107641. european medicines agency schedules indobufen in its extended eudravigilance medicinal product dictionary or xevmpd under index sub08176mig. the term indobufen is an international non-proprietary name or inn (see who inn reference publication, volume 32, no 10 1978, list 18). world health organization schedules indobufen in its anatomical therapeutic chemical (atc) classification. indobufen is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule indobufen under hs 29337900 and sitc 51561. as of q4 2014, indobufen remains the us fda preferred term for this commodity. indobufen bears us nlm identifiers umls id c0063479 and nci concept code c83800. smiles: o=c1n(cc2c1cccc2)c1ccc(c(cc)c(=o)o)cc1.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. melagatran. this classification denotes an anticoagulant agent with the molecular formula c22h31n5o4, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 2a9qp32md4, chemically known as glycine, n-(2-(2-((((4-(aminoiminomethyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)-1-cyclohexyl-2-oxoethyl)-, (s-(r*,s*))- but generally known as melagatran, which bears us nih compound identifier 183797. european medicines agency schedules melagatran in its extended eudravigilance medicinal product dictionary or xevmpd under index sub08718mig. the term melagatran is an international non-proprietary name or inn (see who inn reference publication, volume 10, no. 3, 1996, list 36). world health organization schedules melagatran in its anatomical therapeutic chemical (atc) classification. most nations schedule melagatran under hs 29339990 and sitc 51577. as of q4 2014, melagatran remains the us fda preferred term for this commodity. melagatran bears us nlm identifiers umls id c0668961 and nci concept code c66077. smiles: o=c(n1c(cc1)c(=o)ncc1ccc(cc1)c(=n)n)c(ncc(=o)o)c1ccccc1.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. moxicoumone. this classification denotes an anticoagulant agent with the molecular formula c22h30n2o6, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier ig2442s013, chemically known as 4-methyl-5,7-bis(2-morpholinoethylethoxy)coumarin but generally known as moxicoumone, which bears us nih compound identifier 65686. european medicines agency schedules moxicoumone in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09084mig. the term moxicoumone is an international non-proprietary name or inn (see who inn reference publication, volume 22, no. 10, 1968, list 8). moxicoumone is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule moxicoumone under hs 29349990 and sitc 51579. as of q4 2014, moxicoumone remains the us fda preferred term for this commodity. moxicoumone bears us nlm identifiers umls id c0066835 and nci concept code c66210. smiles: o1ccn(cc1)ccoc1c2c(oc(=o)cc2c)cc(occn2ccocc2)c1.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. napsagatran. this classification denotes an anticoagulant agent, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier vl5izu8pf8. european medicines agency schedules napsagatran in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09161mig. napsagatran generally arises in the molecular formula c26h34n6o6s.h2o. the term napsagatran is an international non-proprietary name or inn (see who inn reference publication, volume 9, no. 3, 1995, list 35.) napsagatran is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule napsagatran under hs 29350090 and sitc 51580. as of q4 2014, napsagatran remains the us fda preferred term for this commodity. napsagatran bears us nlm identifiers umls id c0380191 and nci concept code c90703. smiles: s(=o)(=o)(nc(c(=o)n(c1cc1)cc(=o)o)cc(=o)ncc1cccn(c1)c(=n)n)c1cc2c(cc1)cccc2.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. phenindione. this classification denotes an anticoagulant agent with the molecular formula c15h10o2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 5m7y6274ze, chemically known as 1,3-indandione, 2-phenyl- but generally known as phenindione, which bears us nih compound identifier 4760. european medicines agency schedules phenindione in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09765mig. the term phenindione is an international non-proprietary name. world health organization schedules phenindione in its anatomical therapeutic chemical (atc) classification. phenindione is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule phenindione under hs 29143900 and sitc 51629. as of q4 2014, phenindione remains the us fda preferred term for this commodity. phenindione bears us nlm identifiers umls id c0031406 and nci concept code c66371. smiles: o=c1c(c(=o)c2c1cccc2)c1ccccc1.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. phenprocoumon. this classification denotes an anticoagulant agent with the molecular formula c18h16o3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier q08sio485d, chemically known as 2h-1-benzopyran-2-one, 4-hydroxy-3-(1-phenylpropyl)- but generally known as phenprocoumon, which bears us nih compound identifier 9908. european medicines agency schedules phenprocoumon in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09781mig. the term phenprocoumon is an international non-proprietary name. world health organization schedules phenprocoumon in its anatomical therapeutic chemical (atc) classification. phenprocoumon is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, phenprocoumon remains the us fda preferred term for this commodity. phenprocoumon bears us nlm identifiers umls id c0031444 and nci concept code c66374. smiles: o1c(o)c(c(cc)c2ccccc2)c(=o)c2c1cccc2.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. prasugrel. this classification denotes an antiplatelet agent, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 34k66tbt99. european medicines agency schedules prasugrel in its extended eudravigilance medicinal product dictionary or xevmpd under index sub30236. prasugrel generally arises in the molecular formula c20h20fno3s. the term prasugrel is an international non-proprietary name or inn (see who inn reference publication, volume 19, no. 1, 2005, list 53.) most nations schedule prasugrel under hs 29349990 and sitc 51579. as of q4 2014, prasugrel remains the us fda preferred term for this commodity. prasugrel bears us nlm identifiers umls id c1620287 and nci concept code c81566. smiles: s1c2ccn(c(c(=o)c3cc3)c3c(f)cccc3)cc2cc1oc(=o)c.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. rivaroxaban. this classification denotes an anticoagulant agent with the molecular formula c19h18cln3o5s, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 9ndf7jz4m3, chemically known as 5-chloro-n-(((5s)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)-1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide but generally known as rivaroxaban, which bears us nih compound identifier 6433119. european medicines agency schedules rivaroxaban in its extended eudravigilance medicinal product dictionary or xevmpd under index sub29263. the term rivaroxaban is an international non-proprietary name or inn (see who inn reference publication, volume 18, no. 3, 2004, list 52). world health organization schedules rivaroxaban in its anatomical therapeutic chemical (atc) classification. most nations schedule rivaroxaban under hs 29349990 and sitc 51579. as of q4 2014, rivaroxaban remains the us fda preferred term for this commodity. rivaroxaban bears us nlm identifiers umls id c1739768 and nci concept code c77995. smiles: clc1sc(c(=o)ncc2oc(=o)n(c2)c2ccc(n3ccocc3=o)cc2)cc1.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. sulmarin. this classification denotes a coumarin compound with the molecular formula c10h8o10s2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 73w96524xt, chemically known as 2-(2-methoxy-4-(methylsulfinyl)phenyl)-1h-imidazo(4,5-b)pyridine but generally known as sulmarin, which bears us nih compound identifier 5353. european medicines agency schedules sulmarin in its extended eudravigilance medicinal product dictionary or xevmpd under index sub10747mig. the term sulmarin is an international non-proprietary name or inn (see who inn reference publication, volume 30, no. 10 1976, list 16). sulmarin is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, sulmarin remains the us fda preferred term for this commodity. sulmarin bears us nlm identifiers umls id c2699721 and nci concept code c74242. smiles: coc1=c(c=cc(=c1)s(=o)c)c2=nc3=c(n2)c=cc=n3.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. sulotroban. this classification denotes an antiplatelet agent with the molecular formula c16h17no5s, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 74574co5a6, chemically known as acetic acid, (4-(2-((phenylsulfonyl)amino)ethyl)phenoxy)- but generally known as sulotroban, which bears us nih compound identifier 51550. european medicines agency schedules sulotroban in its extended eudravigilance medicinal product dictionary or xevmpd under index sub10756mig. the term sulotroban is an international non-proprietary name or inn (see who inn reference publication, volume 40, no. 6, 1986, list 26). sulotroban is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule sulotroban under hs 29350090 and sitc 51580. as of q4 2014, sulotroban remains the us fda preferred term for this commodity. sulotroban bears us nlm identifiers umls id c0075621 and nci concept code c84190. smiles: s(=o)(=o)(nccc1ccc(occ(=o)o)cc1)c1ccccc1.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. ticlopidine. this classification denotes a thienopyridine antiplatelet agent with the molecular formula c14h14clns, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier om90zuw7m1, chemically known as 5-((2-chlorophenyl)methyl)-4,5,6,7-tetrahydrothieno(3,2-c)pyridine but generally known as ticlopidine, which bears us nih compound identifier 5472. european medicines agency schedules ticlopidine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub11028mig. the term ticlopidine is an international non-proprietary name or inn (see who inn reference publication, volume 30, no. 10 1976, list 16). world health organization schedules ticlopidine in its anatomical therapeutic chemical (atc) classification. ticlopidine is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule ticlopidine under hs 29349990 and sitc 51579. as of q4 2014, ticlopidine remains the us fda preferred term for this commodity. ticlopidine bears us nlm identifiers umls id c0040207 and nci concept code c61972. smiles: clc1c(cn2ccc3sccc3c2)cccc1.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. tioclomarol. this classification denotes an anticoagulant agent, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier e5b7c16lfk. european medicines agency schedules tioclomarol in its extended eudravigilance medicinal product dictionary or xevmpd under index sub11079mig. tioclomarol generally arises in the molecular formula c22h16cl2o4s. the term tioclomarol is an international non-proprietary name or inn (see who inn reference publication, volume 28, no. 10 1974, list 14.) tioclomarol is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule tioclomarol under hs 29349990 and sitc 51579. as of q4 2014, tioclomarol remains the us fda preferred term for this commodity. tioclomarol bears us nlm identifiers umls id c0612505 and nci concept code c75159. smiles: clc1sc(c(cc(o)c2ccc(cl)cc2)c2c(=o)c3c(oc2o)cccc3)cc1.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. tulopafant. this classification denotes an antiplatelet agent with the molecular formula c25h19n3o2s, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier iq3q8n1287, chemically known as 1h,3h-pyrrolo(1,2-c)thiazole-7-carboxamide, n-(3-(phenylmethyl)phenyl)-3-(3-pyridinyl)-, (+)- but generally known as tulopafant, which bears us nih compound identifier 65927. european medicines agency schedules tulopafant in its extended eudravigilance medicinal product dictionary or xevmpd under index sub11366mig. the term tulopafant is an international non-proprietary name or inn (see who inn reference publication, volume 5, no. 3 1991, list 31). tulopafant is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule tulopafant under hs 29349990 and sitc 51579. as of q4 2014, tulopafant remains the us fda preferred term for this commodity. tulopafant bears us nlm identifiers umls id c2825687 and nci concept code c81573. smiles: s1c(n2c(c1)c(cc2)c(=o)nc1cc(ccc1)c(=o)c1ccccc1)c1cccnc1.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. vapiprost. this classification denotes an antiplatelet agent with the molecular formula c30h39no4, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier h84xt1coau, chemically known as 4-heptenoic acid, 7-(5-((1,1-biphenyl)-4-ylmethoxy)-3-hydroxy-2-(1-piperidinyl)cyclopentyl)-, (1r-(1alpha(z),2beta,3beta,5alpha))- but generally known as vapiprost, which bears us nih compound identifier 6436588. european medicines agency schedules vapiprost in its extended eudravigilance medicinal product dictionary or xevmpd under index sub00025mig. the term vapiprost is an international non-proprietary name or inn (see who inn reference publication, volume 3, no. 3, 1989, list 29). vapiprost is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule vapiprost under hs 29375000 and sitc 54156. as of q4 2014, vapiprost remains the us fda preferred term for this commodity. vapiprost bears us nlm identifiers umls id c0061849 and nci concept code c76408. smiles: o(c1c(c(n2ccccc2)c(o)c1)cc/c=c/ccc(=o)o)cc1ccc(cc1)c1ccccc1.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. ximelagatran. this classification denotes an anticoagulant agent with the molecular formula c24h35n5o5, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 49hfb70472, chemically known as glycine, n-((1r)-1-cyclohexyl-2-((2s)-2-((((4-((hydroxyamino)iminomethyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)-2-oxoethyl)-, ester ester but generally known as ximelagatran, which bears us nih compound identifier 9574101. european medicines agency schedules ximelagatran in its extended eudravigilance medicinal product dictionary or xevmpd under index sub16473mig. the term ximelagatran is an international non-proprietary name or inn (see who inn reference publication, volume 15 no. 3-4, 2001, list 46). world health organization schedules ximelagatran in its anatomical therapeutic chemical (atc) classification. most nations schedule ximelagatran under hs 29339990 and sitc 51577. as of q4 2014, ximelagatran remains the us fda preferred term for this commodity. ximelagatran bears us nlm identifiers umls id c0966370 and nci concept code c77996. smiles: o=c(n1c(cc1)c(=o)ncc1ccc(cc1)c(=n\\o)\\n)c(ncc(=o)occ)c1ccccc1.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. xylocoumarol. this classification denotes a coumarin compound and anticoagulant agent with the molecular formula c17h14o3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier j7i598escc, chemically known as 4-hydroxy-3-(3,5-xylyl)coumarin but generally known as xylocoumarol, which bears us nih compound identifier 27192. european medicines agency schedules xylocoumarol in its extended eudravigilance medicinal product dictionary or xevmpd under index sub00121mig. the term xylocoumarol is an international non-proprietary name. xylocoumarol is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, xylocoumarol remains the us fda preferred term for this commodity. xylocoumarol bears us nlm identifiers umls id c1883580 and nci concept code c66673. smiles: o1c2c(c(=o)c(c3cc(cc(c3)c)c)c1o)cccc2.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. ancrod. this classification denotes an anticoagulant agent, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier el55307l15. european medicines agency schedules ancrod in its extended eudravigilance medicinal product dictionary or xevmpd under index sub00525mig. the term ancrod is an international non-proprietary name or inn (see who inn reference publication, volume 32, no 10 1978, list 18). most nations schedule ancrod under hs 35079090 and sitc 51691. smiles:. as of q4 2014, ancrod remains the us fda preferred term for this commodity. . ancrod bears us nlm identifiers umls id c0002823 and nci concept code c95255.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. danaparoid. this classification denotes a low molecular weight heparin with the molecular formula c14h18no17s2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier bi6gy4u9cw, more generally known as danaparoid. european medicines agency schedules danaparoid in its extended eudravigilance medicinal product dictionary or xevmpd under index sub13531mig. as of q4 2014, danaparoid remains the us fda preferred term for this commodity. smiles: none.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. drotrecogin alfa. this classification denotes an anticoagulant agent with the molecular formula c1786h2779n509o519s29, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier jgh8myc891, chemically known as recombinant human activated protein c but generally known as drotrecogin alfa. european medicines agency schedules drotrecogin alfa in its extended eudravigilance medicinal product dictionary or xevmpd under index sub20025. the term drotrecogin alfa is an international non-proprietary name or inn ( see who inn reference publication, volume 16., no. 1.2002, list 47). most nations schedule drotrecogin alfa under hs 30021095 and sitc 54163. smiles:.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. parnaparin. this classification denotes a low molecular weight heparin with the molecular formula (c14h18no11)n.2(c12h16no13s)n.3ho3s, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier m316wt19d8, chemically known as (4s,6r)-6-[(2r,4r)-4,6-dihydroxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3,4-dihydroxy-5-sulfonatooxyoxane-2-carboxylate, but generally known as parnaparin. european medicines agency schedules parnaparin in its extended eudravigilance medicinal product dictionary or xevmpd under index sub22270. the term parnaparin is an international non-proprietary name or inn (see who inn reference publication, volume 5, no. 3 1991, list 31). as of q4 2014, parnaparin remains the us fda preferred term for this commodity. smiles: c(c1c(c(c(c(o1)o)ns(=o)(=o)[o-])o)oc2c(c(c(c(o2)c(=o)[o-])o)o)os(=o)(=o)[o-])os(=o)(=o)[o-].. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. dabigatran etexilate. this classification denotes an anticoagulant agent, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 2e18wx195x. european medicines agency schedules dabigatran etexilate in its extended eudravigilance medicinal product dictionary or xevmpd under index sub20521. dabigatran etexilate generally arises in the molecular formula c34h41n7o5. the term dabigatran etexilate is an international non-proprietary name or inn (see world health organization inn reference publication, volume 17, no. 2, 2003, list 49.) most nations schedule dabigatran etexilate under hs 29333999 and sitc 51574. as of q4 2014, dabigatran etexilate remains the us fda preferred term for this commodity. dabigatran etexilate bears us nlm identifiers umls id c1571583 and nci concept code c87480. smiles: ccccccoc(=o)/n=c(\\c1ccc(cc1)ncc2nc3cc(ccc3n2c)c(=o)n(ccc(=o)occ)c4ccccn4)/n.. "
"anticoagulants. this classification denotes agents that prevent blood clotting.. antithrombin. antithrombin (at) is a small protein molecule that inactivates several enzymes of the coagulation system. antithrombin is a glycoprotein produced by the liver and consists of 432 amino acids. it contains three disulfide bonds and a total of four possible glycosylation sites.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. . "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. abciximab. this classification denotes a monoclonal antibody with the molecular formula c2101h3229n551o673s15, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier x85g7936gv, more generally known as abciximab. european medicines agency schedules abciximab in its extended eudravigilance medicinal product dictionary or xevmpd under index sub00233mig. the term abciximab is an international non-proprietary name or inn. see who inn reference publication, volume 13 no. 1, 1999, list 41. abciximab is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule abciximab under hs 30021091 and sitc 54163. as of q4 2014, abciximab remains the us fda preferred term for this commodity. abciximab bears us nlm identifiers umls id c0288672 and nci concept code c76128. smiles: none.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. streptokinase. this classification denotes an enzyme produced by hemolytic streptococci and which hydrolyzes amide linkages and serves as an activator of plasminogen, and is thus used in thrombolytic therapy, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 8x1oxl3snu, chemically known as 4-cyclohexylpyrrolidine-2-carboxylic acid but generally known as streptokinase, which bears us nih compound identifier 9815560. european medicines agency schedules streptokinase in its extended eudravigilance medicinal product dictionary or xevmpd under index sub04589mig. the term streptokinase is an international non-proprietary name or inn (see who inn reference publication, volume 13, no. 12, 1959, list 3.) most nations schedule streptokinase under hs 35079090 and sitc 51691. as of q4 2014, streptokinase remains the us fda preferred term for this commodity. smiles: c1ccc(cc1)c2cc(nc2)c(=o)o.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. urokinase. this classification denotes a plasminogen activator with the molecular formula c1376h2145n383o406s18, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 83g67e21xi, more generally known as urokinase. european medicines agency schedules urokinase in its extended eudravigilance medicinal product dictionary or xevmpd under index sub05055mig. the term urokinase is an international non-proprietary name or inn. see who inn reference publication, volume 21 no. 12 1967, list 7. urokinase is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule urokinase under hs 35079090 and sitc 51691. as of q4 2014, urokinase remains the us fda preferred term for this commodity. smiles: none.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. dipyridamole. this classification denotes a phosphodiesterase inhibitor with the molecular formula c24h40n8o4, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 64alc7f90c, chemically known as 2,6-bis(diethanolamino)-4,8-dipiperidinopyrimido(5,4-d)pyrimidine but generally known as dipyridamole, which bears us nih compound identifier 3108. european medicines agency schedules dipyridamole in its extended eudravigilance medicinal product dictionary or xevmpd under index sub07229mig. the term dipyridamole is an international non-proprietary name or inn (see who inn reference publication, volume 19 1975, list 5). world health organization schedules dipyridamole in its anatomical therapeutic chemical (atc) classification. dipyridamole is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule dipyridamole under hs 29335995 and sitc 51576. as of q4 2014, dipyridamole remains the us fda preferred term for this commodity. dipyridamole bears us nlm identifiers umls id c0012582 and nci concept code c445. smiles: occn(c1nc(n2ccccc2)c2nc(nc(n3ccccc3)c2n1)n(cco)cco)cco.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. argatroban. this classification denotes an anticoagulant agent, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier iy90u61z3s. european medicines agency schedules argatroban in its extended eudravigilance medicinal product dictionary or xevmpd under index sub05559mig. argatroban generally arises in the molecular formula c23h36n6o5s. the term argatroban is an international non-proprietary name or inn (see who inn reference publication, volume 12 no. 1 1998, list 39.) argatroban is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule argatroban under hs 29350090 and sitc 51580. as of q4 2014, argatroban remains the us fda preferred term for this commodity. argatroban bears us nlm identifiers umls id c0048470 and nci concept code c28833. smiles: cc1ccn(c(c1)c(=o)o)c(=o)c(cccn=c(n)n)ns(=o)(=o)c2=cc=cc3=c2ncc(c3)c.o.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. eptifibatide. this classification denotes an antiplatelet agent with the molecular formula c35h49n11o9s2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier na8320j834, chemically known as 1,2,3-trihydroxypropanol but generally known as eptifibatide, which bears us nih compound identifier 753. european medicines agency schedules eptifibatide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub12498mig. the term eptifibatide is an international non-proprietary name or inn (see who inn reference publication, volume 12 no. 2 1999, list 40). world health organization schedules eptifibatide in its anatomical therapeutic chemical (atc) classification. eptifibatide is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule eptifibatide under hs 29349990 and sitc 51579. as of q4 2014, eptifibatide remains the us fda preferred term for this commodity. eptifibatide bears us nlm identifiers umls id c0253563 and nci concept code c47516. smiles: oc(co)co.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. tenecteplase. this classification denotes a thrombolytic agent with the molecular formula c2558h3872n738o781s40, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier wgd229o42w, more generally known as tenecteplase. european medicines agency schedules tenecteplase in its extended eudravigilance medicinal product dictionary or xevmpd under index sub04718mig. the term tenecteplase is an international non-proprietary name or inn. see who inn reference publication, volume 13 no. 1, 1999, list 41. most nations schedule tenecteplase under hs 35079090 and sitc 51691. as of q4 2014, tenecteplase remains the us fda preferred term for this commodity. tenecteplase bears us nlm identifiers umls id c0872913 and nci concept code c29489. smiles: none.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. anistreplase. this classification denotes an acylated inactive complex of streptokinase and human lysine-plasminogen; after injection, the acyl group is slowly hydrolyzed, producing an activator that converts plasminogen to plasmin, thereby initiating fibrinolysis, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 5o8v541hj6. european medicines agency schedules anistreplase in its extended eudravigilance medicinal product dictionary or xevmpd under index sub00538mig. the term anistreplase is an international non-proprietary name or inn (see who inn reference publication, volume 3, no. 3, 1989, list 29.) most nations schedule anistreplase under hs 35079090 and sitc 51691. smiles:. as of q4 2014, anistreplase remains the us fda preferred term for this commodity. .. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. reteplase. this classification denotes a plasminogen activator with the molecular formula c1736h2653n499o522s22, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier dqa630rie9, more generally known as reteplase. european medicines agency schedules reteplase in its extended eudravigilance medicinal product dictionary or xevmpd under index sub10290mig. the term reteplase is an international non-proprietary name or inn. see who inn reference publication, volume 8 no. 3 1994, list 34. most nations schedule reteplase under hs 35079090 and sitc 51691. as of q4 2014, reteplase remains the us fda preferred term for this commodity. reteplase bears us nlm identifiers umls id c0106660 and nci concept code c90972. smiles: none.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. dacopafant. this classification denotes an antiplatelet agent with the molecular formula c12h11n3os, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier h1t03z1g60, chemically known as (3r)-3-(3-pyridyl)-1h,3h-pyrrolo(1,2-c)thiazole-7-carboxamide. but generally known as dacopafant, which bears us nih compound identifier 205955. european medicines agency schedules dacopafant in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06886mig. the term dacopafant is an international non-proprietary name or inn (see who inn reference publication, volume 5, no. 3 1991, list 31). dacopafant is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule dacopafant under hs 29349990 and sitc 51579. as of q4 2014, dacopafant remains the us fda preferred term for this commodity. dacopafant bears us nlm identifiers umls id c2348068 and nci concept code c73132. smiles: c1c2=c(c=cn2[c@h](s1)c3=cn=cc=c3)c(=o)n.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. anagrelide. this classification denotes an antiplatelet agent with the molecular formula c10h7cl2n3o, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier k9x45x0051, chemically known as 6,7-dichloro-1,5-dihydroimidazo(2,1-b)quinazolin-2(3h)-one but generally known as anagrelide, which bears us nih compound identifier 2182. anagrelide most often comes in base and hydrochloride forms. european medicines agency schedules anagrelide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub05499mig. the term anagrelide is an international non-proprietary name or inn (see who inn reference publication, volume 34, no. 10 1980, list 20). world health organization schedules anagrelide in its anatomical therapeutic chemical (atc) classification. anagrelide is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule anagrelide under hs 29335995 and sitc 51576. as of q4 2014, anagrelide remains the us fda preferred term for this commodity. anagrelide bears us nlm identifiers umls id c0051809 and nci concept code c28825. smiles: c1c2=c(c=cc(=c2cl)cl)nc3=nc(=o)cn31.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. apafant. this classification denotes an antiplatelet agent with the molecular formula c22h22cln5o2s, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier j613ni05sv, chemically known as 4-(3-(4-(o-chlorophenyl)-9-methyl-6h-thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepin-2-yl)propionyl)morpholine but generally known as apafant, which bears us nih compound identifier 65889. european medicines agency schedules apafant in its extended eudravigilance medicinal product dictionary or xevmpd under index sub05533mig. the term apafant is an international non-proprietary name or inn (see who inn reference publication, volume 3, no. 3, 1989, list 29). apafant is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule apafant under hs 29349990 and sitc 51579. as of q4 2014, apafant remains the us fda preferred term for this commodity. apafant bears us nlm identifiers umls id c0245118 and nci concept code c77989. smiles: clc1c(c2=ncc3n(c4sc(ccc(=o)n5ccocc5)cc24)c(nn3)c)cccc1.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. benzarone. this classification denotes a thrombolytic agent with the molecular formula c17h14o3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 23zw4bg89c, chemically known as methanone, (2-ethyl-3-benzofuranyl)(4-hydroxyphenyl)- but generally known as benzarone, which bears us nih compound identifier 255968. european medicines agency schedules benzarone in its extended eudravigilance medicinal product dictionary or xevmpd under index sub05740mig. the term benzarone is an international non-proprietary name or inn (see who inn reference publication, volume 19 1975, list 5). benzarone is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule benzarone under hs 29329985 and sitc 51569. as of q4 2014, benzarone remains the us fda preferred term for this commodity. benzarone bears us nlm identifiers umls id c0053152 and nci concept code c74411. smiles: o1c(c(c2c1cccc2)c(=o)c1ccc(o)cc1)cc.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. bepafant. this classification denotes an antiplatelet agent with the molecular formula c23h22cln5o2s, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier cks724b66o, chemically known as 4-((6-(o-chlorophenyl)-8,9-dihydro-1-methyl-4h,7h-cyclopenta(4,5)thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepin-8-yl)carbonyl)morpholine but generally known as bepafant, which bears us nih compound identifier 65923. european medicines agency schedules bepafant in its extended eudravigilance medicinal product dictionary or xevmpd under index sub05774mig. the term bepafant is an international non-proprietary name or inn (see who inn reference publication, volume 3, no. 3, 1989, list 29). most nations schedule bepafant under hs 29349990 and sitc 51579. as of q4 2014, bepafant remains the us fda preferred term for this commodity. bepafant bears us nlm identifiers umls id c0378528 and nci concept code c77947. smiles: clc1c(c2=ncc3n(c4sc5cc(cc5c24)c(=o)n2ccocc2)c(nn3)c)cccc1.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. carafiban. this classification denotes a thrombolytic agent with the molecular formula c24h27n5o5, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 39iwk4m2uw, chemically known as ethyl (s)-beta-(2-((s)-4-(p-amidinophenyl)-4-methyl-2,5-dioxo-1-imidazolidinyl)acetamido)hydrocinnamate. but generally known as carafiban, which bears us nih compound identifier 193944. european medicines agency schedules carafiban in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06084mig. the term carafiban is an international non-proprietary name. most nations schedule carafiban under hs 29332990 and sitc 51573. as of q4 2014, carafiban remains the us fda preferred term for this commodity. carafiban bears us nlm identifiers umls id c2698985 and nci concept code c76113. smiles: o=c1n(c(=o)nc1(c1ccc(cc1)c(=n)n)c)cc(=o)nc(cc(=o)occ)c1ccccc1.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. cloricromen. this classification denotes an antiplatelet agent with the molecular formula c20h26clno5, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier b9454pe93c, chemically known as acetic acid, ((8-chloro-3-(2-(diethylamino)ethyl)-4-methyl-2-oxo-2h-1-benzopyran-7-yl)oxy)-, ethyl ester but generally known as cloricromen, which bears us nih compound identifier 68876. european medicines agency schedules cloricromen in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06756mig. the term cloricromen is an international non-proprietary name or inn (see who inn reference publication, volume 39, no. 5, 1985, list 25). world health organization schedules cloricromen in its anatomical therapeutic chemical (atc) classification. cloricromen is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, cloricromen remains the us fda preferred term for this commodity. cloricromen bears us nlm identifiers umls id c0050066 and nci concept code c78091. smiles: clc1c2oc(=o)c(ccn(cc)cc)c(c2ccc1occ(=o)occ)c.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. midazogrel. this classification denotes an antiplatelet agent with the molecular formula c18h24n2o, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 04hck0sd2o, chemically known as 1h-imidazole, 1-(3-(phenylmethoxy)-1-octenyl)-, (e)- but generally known as midazogrel, which bears us nih compound identifier 6436121. european medicines agency schedules midazogrel in its extended eudravigilance medicinal product dictionary or xevmpd under index sub08949mig. the term midazogrel is an international non-proprietary name or inn (see who inn reference publication, volume 39, no. 5, 1985, list 25). midazogrel is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule midazogrel under hs 29332990 and sitc 51573. as of q4 2014, midazogrel remains the us fda preferred term for this commodity. midazogrel bears us nlm identifiers umls id c1881826 and nci concept code c66148. smiles: o(c(ccccc)/c=c/n1ccnc1)cc1ccccc1.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. epoprostenol or prostacyclin. this classification denotes a prostaglandin analogue and antihypertensive agent with the molecular formula c20h32o5, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier dcr9z582x0. european medicines agency schedules epoprostenol in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06581mig. the term epoprostenol is an international non-proprietary name or inn (see who inn reference publication, volume 35, no. 5 1981, list 21. ). epoprostenol is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. epoprostenol or prostacyclin bears us nlm identifiers umls id c0033567 and nci concept code c61748. smiles: cccccc(c=cc1c(cc2c1cc(=ccccc(=o)o)o2)o)o.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. gantofiban. this classification denotes a thrombolytic agent with the molecular formula c21h29n5o6, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier mrg9kh7hf6, chemically known as 4-(((5r)-3-(p-(carboxyamidino)phenyl)-2-oxo-5-oxazolidinyl)methyl)-1-piperazineacetic acid, 1-ethyl methyl ester. but generally known as gantofiban, which bears us nih compound identifier 9578736. the term gantofiban is an international non-proprietary name or inn (see who inn reference publication, volume 13 no. 3, 1999, list 42). most nations schedule gantofiban under hs 29349990 and sitc 51579. as of q4 2014, gantofiban remains the us fda preferred term for this commodity. gantofiban bears us nlm identifiers umls id c1120900 and nci concept code c73227. smiles: cccoc(=o)cn1ccn(cc1)cc2cn(c(=o)o2)c3=cc=c(c=c3)c(=nc(=o)o)n.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. ifetroban. this classification denotes an antiplatelet agent with the molecular formula c25h32n2o5, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier e833kt807k, chemically known as benzenepropanoic acid, 2-((3-(4-((pentylamino)carbonyl)-2-oxazolyl)-7-oxabicyclo(2.2.1)hept-2-yl)methyl)-, (1s-(exo,exo))- but generally known as ifetroban, which bears us nih compound identifier 64924. european medicines agency schedules ifetroban in its extended eudravigilance medicinal product dictionary or xevmpd under index sub08124mig. the term ifetroban is an international non-proprietary name or inn (see who inn reference publication, volume 9, no. 3, 1995, list 35). ifetroban is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule ifetroban under hs 29349990 and sitc 51579. as of q4 2014, ifetroban remains the us fda preferred term for this commodity. ifetroban bears us nlm identifiers umls id c0287939 and nci concept code c81570. smiles: o1c2c(c(c1cc2)c1occ(n1)c(=o)nccccc)cc1c(ccc(=o)o)cccc1.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. iliparcil. this classification denotes a thrombolytic agent, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 753uj7agla. european medicines agency schedules iliparcil in its extended eudravigilance medicinal product dictionary or xevmpd under index sub08131mig. iliparcil generally arises in the molecular formula c15h15clo6s. the term iliparcil is an international non-proprietary name or inn. iliparcil is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule iliparcil under hs 29349990 and sitc 51579. as of q4 2014, iliparcil remains the us fda preferred term for this commodity. iliparcil bears us nlm identifiers umls id c0909750 and nci concept code c83783. smiles: s1c(oc2cc3oc(=o)cc(c3cc2)cc)c(o)c(o)c(o)c1.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. lamifiban. this classification denotes an antiplatelet agent with the molecular formula c24h28n4o6, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 9xoe28082s, chemically known as acetic acid, ((1-(2-((4-aminoiminomethyl)benzoyl)amino)-3-(4-hydroxyphenyl)-1-oxopropyl)-4-piperidinyl)oxy)-, (s)- but generally known as lamifiban, which bears us nih compound identifier 71453. european medicines agency schedules lamifiban in its extended eudravigilance medicinal product dictionary or xevmpd under index sub08391mig. the term lamifiban is an international non-proprietary name or inn (see who inn reference publication, volume 9, no. 3, 1995, list 35). lamifiban is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule lamifiban under hs 29333999 and sitc 51574. as of q4 2014, lamifiban remains the us fda preferred term for this commodity. lamifiban bears us nlm identifiers umls id c0380040 and nci concept code c83862. smiles: o(c1ccn(cc1)c(=o)c(nc(=o)c1ccc(cc1)c(=n)n)cc1ccc(o)cc1)cc(=o)o.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. lotrafiban. this classification denotes an antiplatelet agent with the molecular formula c23h32n4o4, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier klq306i83x, chemically known as 1h-1,4-benzodiazepine-2-acetic acid, 7-((4,4-bipiperidin)-1-ylcarbonyl)-2,3,4,5-tetrahydro-4-methyl-3-oxo-, (2s)- but generally known as lotrafiban, which bears us nih compound identifier 80274. european medicines agency schedules lotrafiban in its extended eudravigilance medicinal product dictionary or xevmpd under index sub08601mig. the term lotrafiban is an international non-proprietary name or inn (see who inn reference publication, volume 12 no. 2 1999, list 40). lotrafiban is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule lotrafiban under hs 29333999 and sitc 51574. as of q4 2014, lotrafiban remains the us fda preferred term for this commodity. lotrafiban bears us nlm identifiers umls id c0960422 and nci concept code c81574. smiles: o=c(n1ccc(c2ccncc2)cc1)c1cc2c(nc(c(=o)n(c2)c)cc(=o)o)cc1.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. setipafant. this classification denotes an antiplatelet agent with the molecular formula c26h23cln6o2s, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier ufn2q54hs6, chemically known as 6-(o-chlorophenyl)-7,10-dihydro-1-methyl-4h-pyrido(4,3:4,5)thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepine-9(8h)-carbox-p-anisidide but generally known as setipafant, which bears us nih compound identifier 65968. european medicines agency schedules setipafant in its extended eudravigilance medicinal product dictionary or xevmpd under index sub10502mig. the term setipafant is an international non-proprietary name or inn (see who inn reference publication, volume 9, no. 3, 1995, list 35). setipafant is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule setipafant under hs 29349990 and sitc 51579. as of q4 2014, setipafant remains the us fda preferred term for this commodity. setipafant bears us nlm identifiers umls id c2699291 and nci concept code c76402. smiles: clc1c(c2=ncc3n(c4sc5c(ccn(c5)c(=o)nc5ccc(oc)cc5)c24)c(nn3)c)cccc1.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. modipafant. this classification denotes an antiplatelet agent with the molecular formula c34h29cln6o3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 1dmi0e5023, chemically known as ethyl ( )-(r)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-2-(p-(2-methyl-1h-imidazo(4,5-c)pyridin-1-yl)phenyl)-5-(2-pyridylcarbamoyl)nicotinate. but generally known as modipafant, which bears us nih compound identifier 3047770. european medicines agency schedules modipafant in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09029mig. the term modipafant is an international non-proprietary name or inn (see who inn reference publication, volume 6, no, 3 1992, list 32). most nations schedule modipafant under hs 29333999 and sitc 51574. as of q4 2014, modipafant remains the us fda preferred term for this commodity. modipafant bears us nlm identifiers umls id c0287533 and nci concept code c90752. smiles: clc1c(c2c(=c(nc(=c2c(=o)nc2ncccc2)c)c2ccc(n3c4c(nc3c)cncc4)cc2)c(=o)occ)cccc1.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. naroparcil. this classification denotes a thrombolytic agent, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 238m5105oy. european medicines agency schedules naroparcil in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09166mig. naroparcil generally arises in the molecular formula c19h17no4s2. the term naroparcil is an international non-proprietary name or inn. naroparcil is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule naroparcil under hs 29349990 and sitc 51579. as of q4 2014, naroparcil remains the us fda preferred term for this commodity. naroparcil bears us nlm identifiers umls id c0294245 and nci concept code c66219. smiles: s1c(sc2ccc(cc2)c(=o)c2ccc(cc2)c#n)c(o)c(o)c(o)c1.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. nicogrelate. this classification denotes an antiplatelet agent, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier dw310svk6q. european medicines agency schedules nicogrelate in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09239mig. nicogrelate generally arises in the molecular formula c17h21n3o2. the term nicogrelate is an international non-proprietary name or inn. nicogrelate is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule nicogrelate under hs 29333999 and sitc 51574. as of q4 2014, nicogrelate remains the us fda preferred term for this commodity. nicogrelate bears us nlm identifiers umls id c2698462 and nci concept code c76399. smiles: o(c(ccccc)/c=c/n1ccnc1)c(=o)c1cccnc1.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. nupafant. this classification denotes an antiplatelet agent with the molecular formula c23h32n4o3s, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 02nki0arrj, chemically known as n-(s)-1-ethoxy-methyl-3-methylbutyl-n-methyl-alpha-(2-methyl-1h-imidazo(4,5-c)pyridin-1-yl)-p-toluenesulfonamide but generally known as nupafant, which bears us nih compound identifier 3047797. european medicines agency schedules nupafant in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09391mig. the term nupafant is an international non-proprietary name or inn (see who inn reference publication, volume 8 no. 3 1994, list 34). nupafant is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule nupafant under hs 29350090 and sitc 51580. as of q4 2014, nupafant remains the us fda preferred term for this commodity. nupafant bears us nlm identifiers umls id c1741717 and nci concept code c81564. smiles: s(=o)(=o)(n(cocc)c)c1c(ccc(c)c)cc(cn2c3c(nc2c)cncc3)cc1.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. ozagrel. this classification denotes an enzyme inhibitor and antiplatelet agent, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier l256jb984d. european medicines agency schedules ozagrel in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09581mig. ozagrel generally arises in the molecular formula c13h12n2o2. the term ozagrel is an international non-proprietary name or inn (see who inn reference publication, volume 40, no. 6, 1986, list 26.) ozagrel is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule ozagrel under hs 29332990 and sitc 51573. as of q4 2014, ozagrel remains the us fda preferred term for this commodity. ozagrel bears us nlm identifiers umls id c0069392 and nci concept code c66288. smiles: cl.oc(=o)/c=c/c1ccc(cn2ccnc2)cc1.o.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. picotamide. this classification denotes an antiplatelet agent with the molecular formula c21h20n4o3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 654g2vci4q, chemically known as 1,3-benzenedicarboxamide, n,n-bis(3-pyridinylmethyl)-4-methoxy- but generally known as picotamide, which bears us nih compound identifier 4814. european medicines agency schedules picotamide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub14868mig. world health organization schedules picotamide in its anatomical therapeutic chemical (atc) classification. as of q4 2014, picotamide remains the us fda preferred term for this commodity. picotamide bears us nlm identifiers umls id c0071043 and nci concept code c73157. smiles: o(c1c(cc(cc1)c(=o)ncc1cccnc1)c(=o)ncc1cccnc1)c. .. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. rocepafant. this classification denotes an antiplatelet agent with the molecular formula c26h23cln6os2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 4kgx1sty2n, chemically known as 6-(o-chlorophenyl)-7,10-dihydro-1-methylthio-4h-pyrido(4,3:4,5)thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepine-9(8h)-carboxy-p-anisidide but generally known as rocepafant, which bears us nih compound identifier 3033963. european medicines agency schedules rocepafant in its extended eudravigilance medicinal product dictionary or xevmpd under index sub10350mig. the term rocepafant is an international non-proprietary name or inn (see who inn reference publication, volume 9, no. 3, 1995, list 35). rocepafant is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule rocepafant under hs 29349990 and sitc 51579. as of q4 2014, rocepafant remains the us fda preferred term for this commodity. rocepafant bears us nlm identifiers umls id c2347968 and nci concept code c73133. smiles: clc1c(c2=ncc3n(c4sc5c(ccn(c5)c(=s)nc5ccc(oc)cc5)c24)c(nn3)c)cccc1.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. taprostene. this classification denotes an antiplatelet agent with the molecular formula c24h30o5, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 7ms1hey2iz, chemically known as benzoic acid, 3-((4-(3-cyclohexyl-3-hydroxy-1-propenyl)hexahydro-5-hydroxy-2h-cyclopenta(b)furan-2-ylidene)methyl)-, (3ar-(2z,3a-alpha,4-alpha(1e,3s*),5-beta,6a-alpha))- but generally known as taprostene, which bears us nih compound identifier 5311243. european medicines agency schedules taprostene in its extended eudravigilance medicinal product dictionary or xevmpd under index sub10831mig. the term taprostene is an international non-proprietary name or inn (see who inn reference publication, volume 2, no. 3, 1988, list 28). taprostene is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule taprostene under hs 29375000 and sitc 54156. as of q4 2014, taprostene remains the us fda preferred term for this commodity. taprostene bears us nlm identifiers umls id c0075812 and nci concept code c76403. smiles: o1c2c(c(c(o)c2)/c=c/c(o)c2ccccc2)cc\\1=c\\c1cc(ccc1)c(=o)o.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. ticagrelor. this classification denotes an antiplatelet agent, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier glh0314rvc. european medicines agency schedules ticagrelor in its extended eudravigilance medicinal product dictionary or xevmpd under index sub30898. ticagrelor generally arises in the molecular formula c23h28f2n6o4s. the term ticagrelor is an international non-proprietary name or inn (see who inn reference publication, volume 21, no. 1, 2007, list 57.) most nations schedule ticagrelor under hs 29335990 and sitc 51576. as of q4 2014, ticagrelor remains the us fda preferred term for this commodity. ticagrelor bears us nlm identifiers umls id c1999375 and nci concept code c76404. smiles: cccsc1=nc2=c(c(=n1)nc3cc3c4=cc(=c(c=c4)f)f)n=nn2c5cc(c(c5o)o)occo.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. trifenagrel. this classification denotes an antiplatelet agent with the molecular formula c25h25n3o, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 59x5me2o06, chemically known as 2-(o-(2-(dimethylamino)ethoxy)phenyl)-4,5-diphenylimidazole but generally known as trifenagrel, which bears us nih compound identifier 72164. european medicines agency schedules trifenagrel in its extended eudravigilance medicinal product dictionary or xevmpd under index sub11282mig. the term trifenagrel is an international non-proprietary name or inn (see who inn reference publication, volume 39, no. 5, 1985, list 25). trifenagrel is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule trifenagrel under hs 29332990 and sitc 51573. as of q4 2014, trifenagrel remains the us fda preferred term for this commodity. trifenagrel bears us nlm identifiers umls id c0637269 and nci concept code c76406. smiles: o(c1c(c2[nh]c(c(n2)c2ccccc2)c2ccccc2)cccc1)ccn(c)c.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. triflusal. this classification denotes an antiplatelet agent with the molecular formula c10h7f3o4, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 1z0yfi05oo, chemically known as 2,4-cresotic acid, alpha,alpha,alpha-trifluoro-, acetate but generally known as triflusal, which bears us nih compound identifier 9458. european medicines agency schedules triflusal in its extended eudravigilance medicinal product dictionary or xevmpd under index sub11292mig. the term triflusal is an international non-proprietary name or inn (see who inn reference publication, volume 31, no10, 1977, list 17). world health organization schedules triflusal in its anatomical therapeutic chemical (atc) classification. triflusal is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule triflusal under hs 29182980 and sitc 51394. as of q4 2014, triflusal remains the us fda preferred term for this commodity. triflusal bears us nlm identifiers umls id c0077126 and nci concept code c76407. smiles: cc(=o)oc1=c(c=cc(=c1)c(f)(f)f)c(=o)o.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. anagrelide hydrochloride monohydrate. this classification denotes the monohydrate form of an antiplatelet agent with the molecular formula c10h7cl2n3o.clh, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier vns4435g39, chemically known as 6,7-dichloro-1,5-dihydroimidazo(2,1-b)-quinazolin-2(3h)-one monohydrochloride but more generally known as anagrelide hydrochloride, which bears us nih compound identifier 42786. european medicines agency schedules anagrelide hydrochloride in its extended eudravigilance medicinal product dictionary or xevmpd under index sub00523mig. most nations, for tariff and trade purposes, schedule anagrelide hydrochloride monohydrate under hs 29335995. as of q4 2014, anagrelide hydrochloride monohydrate remains us fdas preferred term for this commodity. smiles: c1cc(c(c2c1nc3=nc(=o)cn3c2)cl)cl.o.cl.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. argatroban anhydrous. this classification denotes the anhydrous form of an anticoagulant agent, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier iy90u61z3s. european medicines agency schedules argatroban in its extended eudravigilance medicinal product dictionary or xevmpd under index sub05559mig. argatroban generally arises in the molecular formula c23h36n6o5s. the term argatroban is an international non-proprietary name or inn (see world health organization inn reference publication, volume 12 no. 1 1998, list 39.) argatroban is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations, for tariff and trade purposes, schedule argatroban anhydrous under hs 29350090. as of q4 2014, argatroban anhydrous remains us fdas preferred term for this commodity. argatroban anhydrous bears us nlm identifiers umls id c2698183 and nci concept code c75153. smiles: c[c@@h]1ccn([c@h](c1)c(=o)o)c(=o)[c@h](cccnc(=n)n)ns(=o)(=o)c2cccc3c2ncc(c3)c.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. argatroban monohydrate. this classification denotes an anticoagulant agent with the molecular formula c23h36n6o5s.h2o, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier iy90u61z3s, chemically known as 2-piperidinecarboxylic acid, 1-(5-((aminoiminomethyl)amino)-1-oxo-2-(((1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl)amino)pentyl)-4-methyl-, monohydrate, but more generally known as argatroban monohydrate, which bears us nih compound identifier 92721. european medicines agency schedules argatroban monohydrate or its base in its extended eudravigilance medicinal product dictionary or xevmpd under index sub05559mig. most nations, for tariff purposes, schedule argatroban monohydrate under hs 29350090. smiles: c[c@@h]1ccn([c@h](c1)c(=o)o)c(=o)[c@h](cccnc(=n)n)ns(=o)(=o)c2cccc3c2ncc(c3)c.o.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. cloricromen hydrochloride. this classification denotes an antiplatelet agent with the molecular formula c20h26clno5.clh, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 931696ca9t. european medicines agency schedules cloricromen hydrochloride in its extended eudravigilance medicinal product dictionary or xevmpd under index sub01371mig. most nations, for tariff and trade purposes, schedule cloricromen hydrochloride under hs 29322985. as of q4 2014, cloricromen hydrochloride remains us fdas preferred term for this commodity. smiles: ccn(cc)ccc1c(c2ccc(c(c2oc1=o)cl)occ(=o)occ)c.cl.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. epoprostenol sodium. this classification denotes a prostaglandin analogue and antihypertensive agent with the molecular formula c20h31o5.na, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 4k04iq1of4, chemically known as u 53,217a but more generally known as epoprostenol sodium, which bears us nih compound identifier 5282410. european medicines agency schedules epoprostenol sodium in its extended eudravigilance medicinal product dictionary or xevmpd under index sub01918mig. most nations, for tariff and trade purposes, schedule epoprostenol sodium under hs 29375000. as of q4 2014, epoprostenol sodium remains us fdas preferred term for this commodity. epoprostenol sodium bears us nlm identifiers umls id c0354594 and nci concept code c47514. smiles: ccccc[c@@h](/c=c/[c@h]1[c@@h](c[c@h]2[c@@h]1c/c(=c/cccc(=o)[o-])/o2)o)o.[na+].. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. ifetroban sodium. this classification denotes an antiplatelet agent c25h31n2o5.na, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 48ija0e92c, chemically known as benzenepropanoic acid, 2-((3-(4-((pentylamino)carbonyl)-2-oxazolyl)-7-oxabicyclo(2.2.1)hept-2-yl)methyl)-, monosodium salt, (1s-(exo,exo))-, but more generally known as ifetroban sodium, which bears us nih compound identifier 23663994. most nations, for tariff and trade purposes, schedule ifetroban sodium under hs 29349990 and sitc 51579. as of q4 2014, ifetroban sodium remains us fdas preferred term for this commodity. ifetroban sodium bears us nlm identifiers umls id c2825686 and nci concept code c81569. smiles: cccccnc(=o)c1coc(n1)[c@@h]2[c@h]3cc[c@@h]([c@@h]2cc4ccccc4ccc(=o)[o-])o3.[na+].. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. lamifiban hydrochloride. this classification denotes an antiplatelet agent with the molecular formula c24h28n4o6.clh, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 3uz1ctq989, chemically known as (s)-((1-(2-((4-(aminoiminomethyl)benzoyl)amino)-3-(4-hydroxyphenyl)-1-oxopropyl)-4-piperidinyl)oxy)acetic acid monohydrochloride, but more generally known as lamifiban hydrochloride, which bears us nih compound identifier 3038483. european medicines agency schedules lamifiban hydrochloride or its base in its extended eudravigilance medicinal product dictionary or xevmpd under index sub08391mig. most nations, for tariff purposes, schedule lamifiban hydrochloride under hs 29333999. lamifiban hydrochloride bears us nlm identifiers umls id c2825685 and nci concept code c81568. smiles: c1cc(ccc1c[c@@h](c(=o)n2ccc(cc2)occ(=o)o)nc(=o)c3ccc(cc3)c(=n)n)o.cl.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. lotrafiban hydrochloride. this classification denotes an antiplatelet agent c23h32n4o4.clh, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier gsv7v79c63, chemically known as (s)-2,3,4,5-tetrahydro-4-methyl-3-oxo-7-((4-(4-piperidyl)piperidino)carbonyl)-1h-1,4-benzodiazepine-2-acetic acid, monohydrochloride, but more generally known as lotrafiban hydrochloride, which bears us nih compound identifier 80275. most nations, for tariff and trade purposes, schedule lotrafiban hydrochloride under hs 29333999 and sitc 51574. as of q4 2014, lotrafiban hydrochloride remains us fdas preferred term for this commodity. lotrafiban hydrochloride bears us nlm identifiers umls id c1259239 and nci concept code c81572. smiles: cn1cc2cc(ccc2n[c@h](c1=o)cc(=o)o)c(=o)n3ccc(cc3)c4ccncc4.cl.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. ozagrel hydrochloride. this classification denotes an enzyme inhibitor and antiplatelet agent with the molecular formula c13h12n2o2.clh, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier w222u960hs, chemically known as (2e)-3-[4-(1h-imidazol-1-ylmethyl)phenyl]-2-propenoic acid hydrochloride, but more generally known as ozagrel hydrochloride, which bears us nih compound identifier 5282439. european medicines agency schedules ozagrel hydrochloride or its base in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09581mig. most nations, for tariff purposes, schedule ozagrel hydrochloride under hs 29332990. smiles: c1cc(ccc1cn2ccnc2)/c=c/c(=o)o.cl.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. ozagrel hydrochloride hydrate. this classification denotes an enzyme inhibitor and antiplatelet agent with the molecular formula c13h12n2o2.clh.h2o, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier c0i3af4ohv, chemically known as 2-propenoic acid, 3-(4-(1h-imidazol-1-ylmethyl)phenyl)-, hydrochloride, hydrate (1:1:1), but more generally known as ozagrel hydrochloride hydrate, which bears us nih compound identifier 6438130. european medicines agency schedules ozagrel hydrochloride hydrate or its base in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09581mig. most nations, for tariff purposes, schedule ozagrel hydrochloride hydrate under hs 29332990. smiles: c1cc(ccc1cn2ccnc2)/c=c/c(=o)o.o.cl.. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. ozagrel sodium. this classification denotes an enzyme inhibitor and antiplatelet agent c13h11n2o2.na, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 4x5577n3et, chemically known as 2-propenoic acid, 3-(4-(1h-imidazol-1-ylmethyl)phenyl)-, sodium salt (1:1), (2e)-, but more generally known as ozagrel sodium, which bears us nih compound identifier 23663942. european medicines agency schedules ozagrel sodium in its extended eudravigilance medicinal product dictionary or xevmpd under index sub03604mig. most nations, for tariff and trade purposes, schedule ozagrel sodium under hs 29332990 and sitc 51573. as of q4 2014, ozagrel sodium remains us fdas preferred term for this commodity. smiles: c1cc(ccc1cn2ccnc2)/c=c/c(=o)[o-].[na+].. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. taprostene sodium. this classification denotes an antiplatelet agent with the molecular formula c24h29o5.na, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 3m078713kz, chemically known as benzoic acid, 3-((z)-((3ar,4r,5r,6as)-4-((1e,3s)-3-cyclohexyl-3-hydroxy-1-propenyl)hexahydro-5-hydroxy-2h-cyclopenta(b)furan-2-ylidene)methyl)-, monosodium salt, but more generally known as taprostene sodium, which bears us nih compound identifier 6437844. european medicines agency schedules taprostene sodium or its base in its extended eudravigilance medicinal product dictionary or xevmpd under index sub10831mig. most nations, for tariff purposes, schedule taprostene sodium under hs 29375000. smiles: c1cc(cc(c1)c(=o)[o-])/c=c\\2/c[c@h]3[c@@h](o2)c[c@h]([c@@h]3/c=c/[c@h](c4ccccc4)o)o.[na+].. "
"thrombolytic drugs and platelet aggregation inhibitors. this classification denotes drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.. vorapaxar sulfate. a type of protease-activated receptor-1 (par-1) antagonist.. "
"coagulants and systemic hemostatic agents. this classification denotes drugs that cause blood clotting.. . "
"coagulants and systemic hemostatic agents. this classification denotes drugs that cause blood clotting.. fibrinogen. this classification denotes a plasma glycoprotein clotted by thrombin composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds, and which is cleaved by thrombin to form polypeptides a and b, the proteolytic action of other enzymes yields different fibrinogen degradation products, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier n94833051k. european medicines agency schedules fibrinogen in its extended eudravigilance medicinal product dictionary or xevmpd under index sub12502mig. the term fibrinogen is an international non-proprietary name or inn (see who inn reference publication, volume 33, no. 10 1979, list 19.) fibrinogen bears us nlm identifiers umls id c0016006 and nci concept code c25736.. "
"coagulants and systemic hemostatic agents. this classification denotes drugs that cause blood clotting.. antihemophilic factor or globulin. this classification denotes coagulation factor viii, a procoagulant component,a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 839moz74gk. european medicines agency schedules antihemophilic factor in its extended eudravigilance medicinal product dictionary or xevmpd under index sub13813mig.. "
"coagulants and systemic hemostatic agents. this classification denotes drugs that cause blood clotting.. thrombin. this classification denotes an enzyme formed from prothrombin that converts fibrinogen to fibrin, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 25ade2236l. european medicines agency schedules thrombin in its extended eudravigilance medicinal product dictionary or xevmpd under index sub15544mig. the term thrombin is an international non-proprietary name or inn (see who inn reference publication, volume 3, no. 3, 1989, list 29 and see volume 22, no. 1, 2008, list 59). as of q4 2014, thrombin remains the us fda preferred term for this commodity.. "
"coagulants and systemic hemostatic agents. this classification denotes drugs that cause blood clotting.. etamsylate or ethamsylate. this classification denotes a hemostatic and benzenesulfonate with the molecular formula c6h6o5s.c4h11n, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 24yl531voh, chemically known as 2,5-dihydroxybenzenesulfonic acid compound with diethylamine (1:1) but more generally known as etamsylate, which bears us nih compound identifier 17506. european medicines agency schedules etamsylate in its extended eudravigilance medicinal product dictionary or xevmpd under index sub11943mig world health organization schedules etamsylate in its anatomical therapeutic chemical (atc) classification. etamsylate is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. smiles: s(=o)(=o)(o)c1c(o)ccc(o)c1.n(cc)cc.. "
"coagulants and systemic hemostatic agents. this classification denotes drugs that cause blood clotting.. ferric subsulfate. this classification denotes a hemostatic agent, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 3qj8ws6v8h. european medicines agency schedules ferric subsulfate in its extended eudravigilance medicinal product dictionary or xevmpd under index sub33641. ferric subsulfate generally arises in the molecular formula 4fe.5o4s.2ho. the term ferric subsulfate is a u.s. pharmacopeial convention designation. as of q4 2014, ferric subsulfate remains the us fda preferred term for this commodity.. "
"coagulants and systemic hemostatic agents. this classification denotes drugs that cause blood clotting.. aminocaproic acid. this classification denotes a hemostatic agent, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier u6f3787206. european medicines agency schedules aminocaproic acid in its extended eudravigilance medicinal product dictionary or xevmpd under index sub05438mig. aminocaproic acid generally arises in the molecular formula c6h13no2. the term aminocaproic acid is a japanese accepted name designation. most nations schedule aminocaproic acid under hs 29224995 and sitc 51465. as of q4 2014, aminocaproic acid remains the us fda preferred term for this commodity. aminocaproic acid bears us nlm identifiers umls id c0000608 and nci concept code c47391. smiles: c(ccc(=o)o)ccn.. "
"coagulants and systemic hemostatic agents. this classification denotes drugs that cause blood clotting.. calcium dobesilate. this classification denotes a benzenesulfonates and anti-hemorrhagic with the molecular formula 2c6h5o5s.ca, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 5921x1560q, chemically known as 2,5-dihydroxybenzenesulfonic acid calcium salt but generally known as calcium dobesilate, which bears us nih compound identifier 29963. european medicines agency schedules calcium dobesilate in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06051mig. world health organization schedules calcium dobesilate in its anatomical therapeutic chemical (atc) classification. most nations schedule calcium dobesilate under hs 29089910 and sitc 51244. as of q4 2014, calcium dobesilate remains the us fda preferred term for this commodity. smiles: c1=cc(=c(c=c1o)s(=o)(=o)[o-])o.c1=cc(=c(c=c1o)s(=o)(=o)[o-])o.[ca+2].. "
"coagulants and systemic hemostatic agents. this classification denotes drugs that cause blood clotting.. tranexamic acid. this classification denotes a hemostatic agent with the molecular formula c8h15no2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 6t84r30kc1, chemically known as rp 18,429 but generally known as tranexamic acid, which bears us nih compound identifier 5526. european medicines agency schedules tranexamic acid in its extended eudravigilance medicinal product dictionary or xevmpd under index sub11214mig. the term tranexamic acid is an international non-proprietary name or inn (see who inn reference publication, volume 21 no. 12 1967, list 7). world health organization schedules tranexamic acid in its anatomical therapeutic chemical (atc) classification. most nations schedule tranexamic acid under hs 29224995 and sitc 51465. as of q4 2014, tranexamic acid remains the us fda preferred term for this commodity. tranexamic acid bears us nlm identifiers umls id c0040613 and nci concept code c47765. smiles: oc(=o)c1ccc(cc1)cn.. "
"coagulants and systemic hemostatic agents. this classification denotes drugs that cause blood clotting.. romiplostim. this classification denotes a therapeutic colony stimulating factor with the molecular formula c1317h2043n361o395s9, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier gn5xu2dxkv, more generally known as romiplostim. european medicines agency schedules romiplostim in its extended eudravigilance medicinal product dictionary or xevmpd under index sub27756. the term romiplostim is an international non-proprietary name or inn. see who inn reference publication, volume 22, no. 1, 2008, list 59. as of q4 2014, romiplostim remains the us fda preferred term for this commodity.. "
"coagulants and systemic hemostatic agents. this classification denotes drugs that cause blood clotting.. aminomethylbenzoic acid. this classification denotes an antifibrinolytic with the molecular formula c8h9no2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 68wg9jkc7l, 4-aminomethylbenzoic acid or 4-carboxybenzylamine, but generally known as aminomethylbenzoic acid, and which bears us nih compound identifier 65526. european medicines agency schedules aminomethylbenzoic acid in its extended eudravigilance medicinal product dictionary or xevmpd under index sub12854mig. as of q4 2014, aminomethylbenzoic acid remains the us fda preferred term for this commodity. smiles: c1=cc(=cc=c1cn)c(=o)o.. "
"coagulants and systemic hemostatic agents. this classification denotes drugs that cause blood clotting.. aprotinin. this classification denotes a protease inhibitor with the molecular formula c284h432n84o79s7, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 04xpw8c0fl. european medicines agency schedules aprotinin in its extended eudravigilance medicinal product dictionary or xevmpd under index sub05546mig. the term aprotinin is an international non-proprietary name or inn (see who inn reference publication, volume 38, no. 6, 1984, list 24. ). aprotinin is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule aprotinin under hs 29349990 and sitc 51579. as of q4 2014, aprotinin remains the us fda preferred term for this commodity. aprotinin bears us nlm identifiers umls id c0003641 and nci concept code c47402. smiles: s1scc(nc(=o)c(nc(=o)c(nc(=o)c(nc(=o)c2nc(=o)c(nc(=o)c(nc(=o)c(nc(=o)c(nc(=o)c(nc(=o)c(nc(=o)c(nc(=o)c(nc(=o)c(nc(=o)c(nc(=o)c(nc(=o)c(nc(=o)c3nc(=o)cnc(=o)cnc(=o)c(nc(=o)c(nc(=o)c(nc(=o)c(nc(=o)c(nc(=o)c(nc(=o)c(nc(=o)cnc(=o)c(nc(=o)c(nc(=o)c(nc(=o)c(nc(=.. "
"coagulants and systemic hemostatic agents. this classification denotes drugs that cause blood clotting.. camostat. this classification denotes a protease inhibitor with the molecular formula c20h22n4o5, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 0fd207wkdu, chemically known as p-guanidinobenzoic acid, ester with (p-hydroxyphenyl)acetic acid, ester with n,n-dimethylglycolamide but generally known as camostat, which bears us nih compound identifier 2536. camostat most often comes in base and mesilate forms. european medicines agency schedules camostat in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06066mig. the term camostat is an international non-proprietary name. world health organization schedules camostat in its anatomical therapeutic chemical (atc) classification. camostat is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule camostat under hs 29252900 and sitc 51482. as of q4 2014, camostat remains the us fda preferred term for this commodity. camostat bears us nlm identifiers umls id c0129975 and nci concept code c73213. smiles: o(c(=o)cc1ccc(oc(=o)c2ccc(/n=c(/n)n)cc2)cc1)cc(=o)n(c)c.. "
"coagulants and systemic hemostatic agents. this classification denotes drugs that cause blood clotting.. carbazochrome. this classification denotes a hemostatic agent with the molecular formula c10h12n4o3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 81f061rqs4, chemically known as 5,6-indolinedione, 3-hydroxy-1-methyl-, 5-semicarbazone but generally known as carbazochrome, which bears us nih compound identifier 5360410. carbazochrome most often comes in base, salicylate, and sodium sulfonate forms. european medicines agency schedules carbazochrome in its extended eudravigilance medicinal product dictionary or xevmpd under index sub13237mig. the term carbazochrome is an international non-proprietary name or inn (see who inn reference publication, volume 23, no. 10 1969, list 9). world health organization schedules carbazochrome in its anatomical therapeutic chemical (atc) classification. carbazochrome is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule carbazochrome under hs 29339990 and sitc 51577. as of q4 2014, carbazochrome remains the us fda preferred term for this commodity. carbazochrome bears us nlm identifiers umls id c0006972 and nci concept code c79939. smiles: cn1cc(c2=c/c(=n/nc(=o)n)/c(=o)c=c21)o.. "
"coagulants and systemic hemostatic agents. this classification denotes drugs that cause blood clotting.. eltrombopag. this classification denotes an agent affecting blood and body fluid, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier s56d65xj9g. european medicines agency schedules eltrombopag in its extended eudravigilance medicinal product dictionary or xevmpd under index sub30140. eltrombopag generally arises in the molecular formula c25h22n4o4. the term eltrombopag is an international non-proprietary name or inn (see who inn reference publication, volume 20, no. 3, 2006, list 56.) most nations schedule eltrombopag under hs 29331900 and sitc 51571. as of q4 2014, eltrombopag remains the us fda preferred term for this commodity. eltrombopag bears us nlm identifiers umls id c1831905 and nci concept code c71634. smiles: o=c1n([nh]c(c1n/n=c1/c(=o)c(=cc=c1)c1cc(ccc1)c(=o)o)c)c1cc(c(cc1)c)c.. "
"coagulants and systemic hemostatic agents. this classification denotes drugs that cause blood clotting.. batroxobin. this classification denotes a protease inhibitor, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 47ryf40ga9. european medicines agency schedules batroxobin in its extended eudravigilance medicinal product dictionary or xevmpd under index sub00675mig. the term batroxobin is an international non-proprietary name (see who inn reference publication, volume 27, no. 10 1973, list 13.). world health organization schedules camostat in its anatomical therapeutic chemical (atc) classification. batroxobin is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule batroxobin under hs 35079090 and sitc 51691. smiles:. as of q4 2014, batroxobin remains the us fda preferred term for this commodity. . batroxobin bears us nlm identifiers umls id c0035158 and nci concept code c79483.. "
"coagulants and systemic hemostatic agents. this classification denotes drugs that cause blood clotting.. coagulation factor ix. this classification denotes an antifibrinolytic, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 382l14738l. european medicines agency schedules coagulation factor ix in its extended eudravigilance medicinal product dictionary or xevmpd under index sub12030mig. coagulation factor ix bears us nlm identifiers umls id c0015491 and nci concept code c28482.. "
"coagulants and systemic hemostatic agents. this classification denotes drugs that cause blood clotting.. coagulation factor vii. this classification denotes an antifibrinolytic, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 4156xvb4qd. european medicines agency schedules coagulation factor viii in its extended eudravigilance medicinal product dictionary or xevmpd under indices sub32741 and sub13811mig. coagulation factor vii bears us nlm identifiers umls id c0015502 and nci concept code c16570.. "
"coagulants and systemic hemostatic agents. this classification denotes drugs that cause blood clotting.. coagulation factor viii. this classification denotes an antifibrinolytic, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 5t6b772r4q. european medicines agency schedules coagulation factor viii in its extended eudravigilance medicinal product dictionary or xevmpd under index sub13813mig. coagulation factor viii bears us nlm identifiers umls id c0015506 and nci concept code c16571.. "
"coagulants and systemic hemostatic agents. this classification denotes drugs that cause blood clotting.. coagulation factor xiv or protein c. this classification denotes an antifibrinolytic, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier jgh8myc891. european medicines agency schedules coagulation factor xiv in its extended eudravigilance medicinal product dictionary or xevmpd under index sub12567mig.. "
"coagulants and systemic hemostatic agents. this classification denotes drugs that cause blood clotting.. moroctocog alfa. this classification denotes a hemostatic agent with the molecular formula c3953h6020n1040o1158s29/c3553h5412n956o1028s33, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 113e3z3cjj, more generally known as moroctocog alfa. european medicines agency schedules moroctocog alfa in its extended eudravigilance medicinal product dictionary or xevmpd under index sub16445mig. the term moroctocog alfa is an international non-proprietary name or inn. see who inn reference publication, volume 9, no. 3, 1995, list 35.. "
"coagulants and systemic hemostatic agents. this classification denotes drugs that cause blood clotting.. camostat mesilate or mesylate. this classification denotes a protease inhibitor with the molecular formula c20h22n4o5.ch4o3s, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 451m50a1eq, chemically known as p-(p-guanidinobenzoyloxy)phenyl acetic acid, n,n-dimethylcarbamoylmethyl ester but more generally known as camostat mesilate, which bears us nih compound identifier 43071. european medicines agency schedules camostat mesilate in its extended eudravigilance medicinal product dictionary or xevmpd under index sub01007mig. most nations, for tariff and trade purposes, schedule camostat mesylate under hs 29252900. as of q4 2014, camostat mesylate remains us fdas preferred term for this commodity. camostat mesylate bears us nlm identifiers umls id c0060700 and nci concept code c96364. smiles: cn(c)c(=o)coc(=o)cc1ccc(cc1)oc(=o)c2ccc(cc2)nc(=n)n.cs(=o)(=o)o.. "
"coagulants and systemic hemostatic agents. this classification denotes drugs that cause blood clotting.. carbazochrome salicylate. this classification denotes a hemostatic agent, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 3h4od401lf. european medicines agency schedules carbazochrome salicylate in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06119mig. carbazochrome salicylate generally arises in the molecular formula c10h12n4o3.c7h6o3.na. the term carbazochrome salicylate is an international non-proprietary name or inn (see world health organization inn reference publication, volume 13, no. 12, 1959, list 3.) most nations, for tariff and trade purposes, schedule carbazochrome salicylate under hs 30039090 and sitc 54291. as of q4 2014, carbazochrome salicylate remains us fdas preferred term for this commodity. carbazochrome salicylate bears us nlm identifiers umls id c0006973 and nci concept code c76883. smiles: cn1cc(c2=c/c(=n/nc(=o)n)/c(=o)c=c21)o.c1ccc(c(c1)c(=o)[o-])o.[na+].. "
"coagulants and systemic hemostatic agents. this classification denotes drugs that cause blood clotting.. carbazochrome sodium sulfonate. this classification denotes a hemostatic agent with the molecular structure c10h11n4o5s.na, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier, j0i08m946e chemically known as sodium salt of 5,6-dihydro-1-methyl-5,6-dioxo-3-indoline sulfonic acid 5-semicarbazone, but more commonly known as carbazochrome sodium sulfonate, which bears us nih compound identifier 6321410. european medicines agency schedules carbazochrome sodium sulfonate in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06120mig. the term carbazochrome sodium sulfonate is an international non-proprietary name or inn (see world health organization inn reference publication, volume 16, no. 3 1962, list 4. ). most nations, for tariff and trade purposes, schedule carbazochrome sodium sulfonate under hs 29339990 and sitc 51577. as of q4 2014, carbazochrome sodium sulfonate remains us fdas preferred term for this commodity. carbazochrome sodium sulfonate bears us nlm identifiers umls id c0054657 and nci concept code c83589. smiles: cn1c(cc2=c/c(=n/nc(=o)n)/c(=o)c=c21)s(=o)(=o)[o-].[na+].. "
"coagulants and systemic hemostatic agents. this classification denotes drugs that cause blood clotting.. eltrombopag olamine. this classification denotes an agent affecting blood and body fluid c25h22n4o4.2c2h7no, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 4u07f515lg, chemically known as (1,1-biphenyl)-3-carboxylic acid, 3-((2z)-(1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene)hydrazino)-2-hydroxy-, compound with 2-aminoethanol (1:2), but more generally known as eltrombopag olamine, which bears us nih compound identifier 9915926. european medicines agency schedules eltrombopag olamine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub30141. most nations, for tariff and trade purposes, schedule eltrombopag olamine under hs 29331900 and sitc 51571. as of q4 2014, eltrombopag olamine remains us fdas preferred term for this commodity. eltrombopag olamine bears us nlm identifiers umls id c1880492 and nci concept code c62501. smiles: cc1ccc(cc1c)n2c(=o)/c(=n\\nc3cccc(c3o)c4cccc(c4)c(=o)o)/c(=n2)c.c(co)n.c(co)n.. "
"blood plasma substitutes and extenders and expanders. this classification denotes substances, such as erythrocyte, hemoglobin, or red cell substitutes or artificial hemoglobin, that are used in place of blood, for example, as an alternative to blood transfusions after blood loss to restore blood volume and oxygen-carrying capacity to the blood circulation, or to perfuse isolated organs.. . "
"blood plasma substitutes and extenders and expanders. this classification denotes substances, such as erythrocyte, hemoglobin, or red cell substitutes or artificial hemoglobin, that are used in place of blood, for example, as an alternative to blood transfusions after blood loss to restore blood volume and oxygen-carrying capacity to the blood circulation, or to perfuse isolated organs.. poligeline or polygeline. this classification denotes a 3.5 per cent colloidal solution containing urea-cross-linked polymerized peptides, with a molecular weight of approximately 35,000, and which manufacturers derive from from gelatin and electrolytes, into a polymeric solution that serves as a plasma expander. european medicines agency schedules polygeline (or poligeline) in its extended eudravigilance medicinal product dictionary or xevmpd under index sub03935mig.. "
"blood plasma substitutes and extenders and expanders. this classification denotes substances, such as erythrocyte, hemoglobin, or red cell substitutes or artificial hemoglobin, that are used in place of blood, for example, as an alternative to blood transfusions after blood loss to restore blood volume and oxygen-carrying capacity to the blood circulation, or to perfuse isolated organs.. human blood plasma. this classification denotes a protein-based fluid (sometimes also called simulated body fluid) or that residual portion of blood that is left after removal of blood cells by centrifugation without prior blood coagulation, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 839moz74gk. european medicines agency schedules human blood plasma in its extended eudravigilance medicinal product dictionary or xevmpd under index sub51727.. "
"blood plasma substitutes and extenders and expanders. this classification denotes substances, such as erythrocyte, hemoglobin, or red cell substitutes or artificial hemoglobin, that are used in place of blood, for example, as an alternative to blood transfusions after blood loss to restore blood volume and oxygen-carrying capacity to the blood circulation, or to perfuse isolated organs.. pentastarch. this classification denotes a carbohydrate, polysaccharide, and glucan, and a derivative of starch used as a plasma substitute in the treatment of hemorrhage, also sometimes called hetastarch, a preparation that typically bears the molecular formula c29h52o21 and which is chemically known as 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol, but generally known as pentastarch, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier moq3rnm0s, which bears us nih compound identifier 24846132. european medicines agency schedules pentastarch and hetastarch in its extended eudravigilance medicinal product dictionary or xevmpd under indices sub20665 and sub14097mig. as of q4 2014, pentastarch remains the us fda preferred term for this commodity. smiles: cc1c(c(c(c(o1)co)oc2c(c(c(c(o2)coc3c(c(c(c(o3)co)oc)o)o)oc4c(c(c(c(o4)co)oc)o)occo)o)o)o)o.. "
"blood plasma substitutes and extenders and expanders. this classification denotes substances, such as erythrocyte, hemoglobin, or red cell substitutes or artificial hemoglobin, that are used in place of blood, for example, as an alternative to blood transfusions after blood loss to restore blood volume and oxygen-carrying capacity to the blood circulation, or to perfuse isolated organs.. human plasma protein fraction. this classification denotes a protein-based fluid (sometimes also called simulated body fluid) or that residual portion of blood that is left after removal of blood cells by centrifugation without prior blood coagulation, and proteins extracted therefrom, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 6d53g0fd0z. european medicines agency schedules human plasma protein fraction in its extended eudravigilance medicinal product dictionary or xevmpd under indices sub51727 and sub22285 and sub32334.. "
"blood plasma substitutes and extenders and expanders. this classification denotes substances, such as erythrocyte, hemoglobin, or red cell substitutes or artificial hemoglobin, that are used in place of blood, for example, as an alternative to blood transfusions after blood loss to restore blood volume and oxygen-carrying capacity to the blood circulation, or to perfuse isolated organs.. hetastarch. this classification denotes a blood substitute, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 875y4127ea. european medicines agency schedules hetastarch in its extended eudravigilance medicinal product dictionary or xevmpd under index sub14097mig. hetastarch generally arises in the molecular formula (c6h7o5)n.c2h5o.h. the term hetastarch is an fda designation. as of q4 2014, hetastarch remains the us fda preferred term for this commodity. hetastarch bears us nlm identifiers umls id c0020352 and nci concept code c559. smiles: cc1c(c(c(c(o1)co)oc2c(c(c(c(o2)coc3c(c(c(c(o3)co)oc)o)o)oc4c(c(c(c(o4)co)oc)o)occo)o)o)o)o.. "
"blood plasma substitutes and extenders and expanders. this classification denotes substances, such as erythrocyte, hemoglobin, or red cell substitutes or artificial hemoglobin, that are used in place of blood, for example, as an alternative to blood transfusions after blood loss to restore blood volume and oxygen-carrying capacity to the blood circulation, or to perfuse isolated organs.. albumin human. this classification denotes a peptide fragment derived from human blood plasma, or that residual portion of blood that is left after removal of blood cells by centrifugation without prior blood coagulation, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier zif514rvzr. european medicines agency schedules albumin human in its extended eudravigilance medicinal product dictionary or xevmpd under indices sub12026mig, sub12761mig, sub50207, and sub62389. as of q4 2014, albumin human remains the us fda preferred term for this commodity.. "
"blood plasma substitutes and extenders and expanders. this classification denotes substances, such as erythrocyte, hemoglobin, or red cell substitutes or artificial hemoglobin, that are used in place of blood, for example, as an alternative to blood transfusions after blood loss to restore blood volume and oxygen-carrying capacity to the blood circulation, or to perfuse isolated organs.. dextran. this classification denotes a blood substitute, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 7sa290yk68. european medicines agency schedules dextran 70 in its extended eudravigilance medicinal product dictionary or xevmpd under index sub01638mig. dextran 70 generally arises in the molecular formula c12h22o11(c6h10o5)n. the term dextran 70 is a united states adopted name designation. most nations schedule dextran under hs 39139000 and sitc 57595. smiles: c(c1c(c(c(c(o1)occ2c(c(c(c(o2)occ(c(c(c(c=o)o)o)o)o)o)o)o)o)o)o)o.. "
"hemorrheologic agents. this classification denotes drugs that improve blood flow by various mechanisms, such as increasing erythrocyte and leukocyte flexibility.. . "
"hemorrheologic agents. this classification denotes drugs that improve blood flow by various mechanisms, such as increasing erythrocyte and leukocyte flexibility.. pentoxifylline. this classification denotes a phosphodiesterase inhibitor and antiplatelet agent and alkaloid with the molecular formula c13h18n4o3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier sd6qct3tsu, chemically known as 1,2,3,6-tetrahydro-3,7-dimethyl-1-(5-oxohexyl)-2,6-purindion but generally known as pentoxifylline, which bears us nih compound identifier 4740. european medicines agency schedules pentoxifylline in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09705mig. the term pentoxifylline is an international non-proprietary name or inn (see who inn reference publication, volume 27, no. 10 1973, list 13). world health organization schedules pentoxifylline in its anatomical therapeutic chemical (atc) classification. pentoxifylline is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule pentoxifylline under hs 29395900 and sitc 54145. as of q4 2014, pentoxifylline remains the us fda preferred term for this commodity. pentoxifylline bears us nlm identifiers umls id c0030899 and nci concept code c733. smiles: cc(=o)ccccn1c(=o)c2=c(n=cn2c)n(c1=o)c.. "
"combination hematolic drugs. this classification denotes combination drugs that act on blood and blood-forming organs and those that affect the hemostatic system.. . "
"combination hematolic drugs. this classification denotes combination drugs that act on blood and blood-forming organs and those that affect the hemostatic system.. heparin/sodium chloride. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class bl110. this va drug class (bl110) classifies this compound as belonging to the group anticoagulants.. "
"combination hematolic drugs. this classification denotes combination drugs that act on blood and blood-forming organs and those that affect the hemostatic system.. aspirin/dipyridamole. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class bl117. this va drug class (bl117) classifies this compound as belonging to the group platelet aggregation inhibitors.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. . "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. acetaminophen/caffeine. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics. the first component of this combination drug is an analgesic and antipyretic with the molecular formula c8h9no2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 362o9itl9d, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears u.s. national institutes of health compound identifier 1983. acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. the european medicines agency schedules acetaminophen in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09611mig. the world health organization schedules acetaminophen in its anatomical therapeutic chemical (atc) classification. the second component of this combination drug is a cns stimulant and bioactive food component with the molecular formula c8h10n4o2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 3g6a5w338e, chemically known as 1,3,7-trimethylxanthine but more generally known as caffeine, which bears u.s. national institutes of health compound identifier 2519. caffeine comes in many forms, including base, benzoate, benzoate sodium, bromide, citrate, hydrobromide, hydrochloride, hydroiodide, monohydrate, salicylate, sodium benzoate, sodium benzoicum, and sodium salicylate. the european medicines agency schedules caffeine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub13146mig. the world health organization schedules caffeine in its anatomical therapeutic chemical (atc) classification.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. acetaminophen/aluminum hydroxide/aspirin/caffeine/magnesium hydr. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics. the first component of this combination drug is an analgesic and antipyretic with the molecular formula c8h9no2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 362o9itl9d, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears u.s. national institutes of health compound identifier 1983. acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. the european medicines agency schedules acetaminophen in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09611mig. the world health organization schedules acetaminophen in its anatomical therapeutic chemical (atc) classification. the second component of this combination drug is a common antacid with the molecular formula al.3ho, a compound that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 5qb0t2iun0, which is chemically known as aluminium(3+) trioxidanide but which is more generally known as aluminum hydroxide, which bears u.s. national institutes of health compound identifier 115283. the european medicines agency schedules aluminum hydroxide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub11700mig. the third component of this combination drug is a cyclooxygenase inhibitor with the molecular formula c9h8o4, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier r16co5y76e, chemically known as salicylic acid, acetyl- but more generally known as acetylsalicylic acid, which bears u.s. national institutes of health compound identifier 2244. the european medicines agency schedules acetylsalicylic acid in its extended eudravigilance medicinal product dictionary or xevmpd under index sub12730mig. the world health organization schedules acetylsalicylic acid in its anatomical therapeutic chemical (atc) classification. the fourth component of this combination drug is a cns stimulant and bioactive food component with the molecular formula c8h10n4o2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 3g6a5w338e, chemically known as 1,3,7-trimethylxanthine but more generally known as caffeine, which bears u.s. national institutes of health compound identifier 2519. caffeine comes in many forms, including base, benzoate, benzoate sodium, bromide, citrate, hydrobromide, hydrochloride, hydroiodide, monohydrate, salicylate, sodium benzoate, sodium benzoicum, and sodium salicylate. the european medicines agency schedules caffeine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub13146mig. the world health organization schedules caffeine in its anatomical therapeutic chemical (atc) classification. the fifth component of this combination drug is an antacid with the molecular formula mg.2ho, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier nbz3qy004s, chemically known as magnesium ion, 2 waters coordinated but more generally known as magnesium hydroxide, which bears u.s. national institutes of health compound identifier 14791. the european medicines agency schedules magnesium hydroxide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub14429mig. the world health organization schedules magnesium hydroxide in its anatomical therapeutic chemical (atc) classification.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. acetaminophen/aluminum hydroxide/aspirin/salicylamide. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics. the first component of this combination drug is an analgesic and antipyretic with the molecular formula c8h9no2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 362o9itl9d, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears u.s. national institutes of health compound identifier 1983. acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. the european medicines agency schedules acetaminophen in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09611mig. the world health organization schedules acetaminophen in its anatomical therapeutic chemical (atc) classification. the second component of this combination drug is a common antacid with the molecular formula al.3ho, a compound that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 5qb0t2iun0, which is chemically known as aluminium(3+) trioxidanide but which is more generally known as aluminum hydroxide, which bears u.s. national institutes of health compound identifier 115283. the european medicines agency schedules aluminum hydroxide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub11700mig. the third component of this combination drug is a cyclooxygenase inhibitor with the molecular formula c9h8o4, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier r16co5y76e, chemically known as salicylic acid, acetyl- but more generally known as acetylsalicylic acid, which bears u.s. national institutes of health compound identifier 2244. the european medicines agency schedules acetylsalicylic acid in its extended eudravigilance medicinal product dictionary or xevmpd under index sub12730mig. the world health organization schedules acetylsalicylic acid in its anatomical therapeutic chemical (atc) classification. the fourth component of this combination drug is a nonsteroidal antiinflammatory drug, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier em8bm710zc. the european medicines agency schedules salicylamide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub10426mig. salicylamide generally arises in the molecular formula c7h7no2. the term salicylamide is an international non-proprietary name or inn.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. acetaminophen/aspirin. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. acetaminophen/aspirin/caffeine. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics. the first component of this combination drug is an analgesic and antipyretic with the molecular formula c8h9no2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 362o9itl9d, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears u.s. national institutes of health compound identifier 1983. acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. the european medicines agency schedules acetaminophen in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09611mig. the world health organization schedules acetaminophen in its anatomical therapeutic chemical (atc) classification. the second component of this combination drug is a cyclooxygenase inhibitor with the molecular formula c9h8o4, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier r16co5y76e, chemically known as salicylic acid, acetyl- but more generally known as acetylsalicylic acid, which bears u.s. national institutes of health compound identifier 2244. the european medicines agency schedules acetylsalicylic acid in its extended eudravigilance medicinal product dictionary or xevmpd under index sub12730mig. the world health organization schedules acetylsalicylic acid in its anatomical therapeutic chemical (atc) classification. the third component of this combination drug is a cns stimulant and bioactive food component with the molecular formula c8h10n4o2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 3g6a5w338e, chemically known as 1,3,7-trimethylxanthine but more generally known as caffeine, which bears u.s. national institutes of health compound identifier 2519. caffeine comes in many forms, including base, benzoate, benzoate sodium, bromide, citrate, hydrobromide, hydrochloride, hydroiodide, monohydrate, salicylate, sodium benzoate, sodium benzoicum, and sodium salicylate. the european medicines agency schedules caffeine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub13146mig. the world health organization schedules caffeine in its anatomical therapeutic chemical (atc) classification.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. acetaminophen/aspirin/caffeine/calcium gluconate. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics. the first component of this combination drug is an analgesic and antipyretic with the molecular formula c8h9no2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 362o9itl9d, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears u.s. national institutes of health compound identifier 1983. acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. the european medicines agency schedules acetaminophen in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09611mig. the world health organization schedules acetaminophen in its anatomical therapeutic chemical (atc) classification. the second component of this combination drug is a cyclooxygenase inhibitor with the molecular formula c9h8o4, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier r16co5y76e, chemically known as salicylic acid, acetyl- but more generally known as acetylsalicylic acid, which bears u.s. national institutes of health compound identifier 2244. the european medicines agency schedules acetylsalicylic acid in its extended eudravigilance medicinal product dictionary or xevmpd under index sub12730mig. the world health organization schedules acetylsalicylic acid in its anatomical therapeutic chemical (atc) classification. the third component of this combination drug is a cns stimulant and bioactive food component with the molecular formula c8h10n4o2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 3g6a5w338e, chemically known as 1,3,7-trimethylxanthine but more generally known as caffeine, which bears u.s. national institutes of health compound identifier 2519. caffeine comes in many forms, including base, benzoate, benzoate sodium, bromide, citrate, hydrobromide, hydrochloride, hydroiodide, monohydrate, salicylate, sodium benzoate, sodium benzoicum, and sodium salicylate. the european medicines agency schedules caffeine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub13146mig. the world health organization schedules caffeine in its anatomical therapeutic chemical (atc) classification. the fourth component of this combination drug is an electrolyte replacement agent with the molecular formula 2c6h11o7.ca, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier sqe6vb453k, chemically known as gluconic acid, calcium salt but more generally known as calcium gluconate, which bears u.s. national institutes of health compound identifier 9290. the european medicines agency schedules calcium gluconate in its extended eudravigilance medicinal product dictionary or xevmpd under index sub13176mig. the world health organization schedules calcium gluconate in its anatomical therapeutic chemical (atc) classification.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. acetaminophen/aspirin/caffeine/salicylamide. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics. the first component of this combination drug is an analgesic and antipyretic with the molecular formula c8h9no2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 362o9itl9d, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears u.s. national institutes of health compound identifier 1983. acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. the european medicines agency schedules acetaminophen in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09611mig. the world health organization schedules acetaminophen in its anatomical therapeutic chemical (atc) classification. the second component of this combination drug is a cyclooxygenase inhibitor with the molecular formula c9h8o4, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier r16co5y76e, chemically known as salicylic acid, acetyl- but more generally known as acetylsalicylic acid, which bears u.s. national institutes of health compound identifier 2244. the european medicines agency schedules acetylsalicylic acid in its extended eudravigilance medicinal product dictionary or xevmpd under index sub12730mig. the world health organization schedules acetylsalicylic acid in its anatomical therapeutic chemical (atc) classification. the third component of this combination drug is a cns stimulant and bioactive food component with the molecular formula c8h10n4o2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 3g6a5w338e, chemically known as 1,3,7-trimethylxanthine but more generally known as caffeine, which bears u.s. national institutes of health compound identifier 2519. caffeine comes in many forms, including base, benzoate, benzoate sodium, bromide, citrate, hydrobromide, hydrochloride, hydroiodide, monohydrate, salicylate, sodium benzoate, sodium benzoicum, and sodium salicylate. the european medicines agency schedules caffeine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub13146mig. the world health organization schedules caffeine in its anatomical therapeutic chemical (atc) classification. the fourth component of this combination drug is a nonsteroidal antiinflammatory drug, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier em8bm710zc. the european medicines agency schedules salicylamide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub10426mig. salicylamide generally arises in the molecular formula c7h7no2. the term salicylamide is an international non-proprietary name or inn.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. acetaminophen/aspirin/calcium carbonate. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics. the first component of this combination drug is an analgesic and antipyretic with the molecular formula c8h9no2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 362o9itl9d, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears u.s. national institutes of health compound identifier 1983. acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. the european medicines agency schedules acetaminophen in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09611mig. the world health organization schedules acetaminophen in its anatomical therapeutic chemical (atc) classification. the second component of this combination drug is a cyclooxygenase inhibitor with the molecular formula c9h8o4, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier r16co5y76e, chemically known as salicylic acid, acetyl- but more generally known as acetylsalicylic acid, which bears u.s. national institutes of health compound identifier 2244. the european medicines agency schedules acetylsalicylic acid in its extended eudravigilance medicinal product dictionary or xevmpd under index sub12730mig. the world health organization schedules acetylsalicylic acid in its anatomical therapeutic chemical (atc) classification. the third component of this combination drug is a nutritional supplement with the molecular formula co3.ca, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier h0g9379fgk, chemically known as carbonic acid, calcium salt (1:1) but more generally known as calcium carbonate, which bears u.s. national institutes of health compound identifier 10112. the european medicines agency schedules calcium carbonate in its extended eudravigilance medicinal product dictionary or xevmpd under index sub13166mig. the world health organization schedules calcium carbonate in its anatomical therapeutic chemical (atc) classification.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. acetaminophen/butalbital. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics. the first component of this combination drug is an analgesic and antipyretic with the molecular formula c8h9no2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 362o9itl9d, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears u.s. national institutes of health compound identifier 1983. acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. the european medicines agency schedules acetaminophen in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09611mig. the world health organization schedules acetaminophen in its anatomical therapeutic chemical (atc) classification. the second component of this combination drug is a barbiturate with the molecular formula c11h16n2o3, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier khs0az4jvk, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(2-methylpropyl)-5-(2-propenyl)- but more generally known as butalbital, which bears u.s. national institutes of health compound identifier 2481. butalbital most often comes in base and sodium forms. the european medicines agency schedules butalbital in its extended eudravigilance medicinal product dictionary or xevmpd under index sub05999mig. the term butalbital is an international non-proprietary name or inn (see world health organization inn reference publication, volume 23, no. 10 1969, list 9).. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. acetaminophen/butalbital/caffeine. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics. the first component of this combination drug is an analgesic and antipyretic with the molecular formula c8h9no2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 362o9itl9d, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears u.s. national institutes of health compound identifier 1983. acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. the european medicines agency schedules acetaminophen in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09611mig. the world health organization schedules acetaminophen in its anatomical therapeutic chemical (atc) classification. the second component of this combination drug is a barbiturate with the molecular formula c11h16n2o3, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier khs0az4jvk, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(2-methylpropyl)-5-(2-propenyl)- but more generally known as butalbital, which bears u.s. national institutes of health compound identifier 2481. butalbital most often comes in base and sodium forms. the european medicines agency schedules butalbital in its extended eudravigilance medicinal product dictionary or xevmpd under index sub05999mig. the term butalbital is an international non-proprietary name or inn (see world health organization inn reference publication, volume 23, no. 10 1969, list 9). the third component of this combination drug is a cns stimulant and bioactive food component with the molecular formula c8h10n4o2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 3g6a5w338e, chemically known as 1,3,7-trimethylxanthine but more generally known as caffeine, which bears u.s. national institutes of health compound identifier 2519. caffeine comes in many forms, including base, benzoate, benzoate sodium, bromide, citrate, hydrobromide, hydrochloride, hydroiodide, monohydrate, salicylate, sodium benzoate, sodium benzoicum, and sodium salicylate. the european medicines agency schedules caffeine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub13146mig. the world health organization schedules caffeine in its anatomical therapeutic chemical (atc) classification.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. acetaminophen/pamabrom/pyrilamine. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf) which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics. the first component of this combination drug is an analgesic and antipyretic with the molecular formula c8h9no2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 362o9itl9d, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears u.s. national institutes of health compound identifier 1983. acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. the european medicines agency schedules acetaminophen in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09611mig. the world health organization schedules acetaminophen in its anatomical therapeutic chemical (atc) classification. the second component of this combination drug is a diuretic with the molecular formula c7h7brn4o2.c4h11no, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier ua8u0kjm72, chemically known as 8-bromo-3,7-dihydro-1,3-dimethyl-1h-purine-2,6-dione compound with 2-amino-2-methyl-1-propanol (1:1) but more generally known as pamabrom, which bears u.s. national institutes of health compound identifier 11806. the european medicines agency schedules pamabrom in its extended eudravigilance medicinal product dictionary or xevmpd under index sub14745mig. the third component of this combination drug is the fifth component of this combination drug is a histamine-1 receptor antagonist with the molecular formula c17h23n3o, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier hpe317o9tl, chemically known as n,n-dimethyl-n-(p-methoxybenzyl)-n-(2-pyridyl)ethylenediamine but more generally known as pyrilamine, which bears u.s. national institutes of health compound identifier 4992.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. acetaminophen/caffeine/hyoscyamus. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics. the first component of this combination drug is an analgesic and antipyretic with the molecular formula c8h9no2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 362o9itl9d, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears u.s. national institutes of health compound identifier 1983. acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. the european medicines agency schedules acetaminophen in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09611mig. the world health organization schedules acetaminophen in its anatomical therapeutic chemical (atc) classification. the second component of this combination drug is a cns stimulant and bioactive food component with the molecular formula c8h10n4o2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 3g6a5w338e, chemically known as 1,3,7-trimethylxanthine but more generally known as caffeine, which bears u.s. national institutes of health compound identifier 2519. caffeine comes in many forms, including base, benzoate, benzoate sodium, bromide, citrate, hydrobromide, hydrochloride, hydroiodide, monohydrate, salicylate, sodium benzoate, sodium benzoicum, and sodium salicylate. the european medicines agency schedules caffeine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub13146mig. the third component of this combination drug is a natural product known to us fda as an active ingredient or moiety under unique ingredient identifier 32it7g8baw, and is more generally known as hyoscyamus. the european medicines agency schedules hyoscyamus in its extended eudravigilance medicinal product dictionary or xevmpd under index sub14163mig.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. acetaminophen/caffeine/phenyltoloxamine/salicylamide. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics. the first component of this combination drug is an analgesic and antipyretic with the molecular formula c8h9no2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 362o9itl9d, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears u.s. national institutes of health compound identifier 1983. acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. the european medicines agency schedules acetaminophen in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09611mig. the world health organization schedules acetaminophen in its anatomical therapeutic chemical (atc) classification. the second component of this combination drug is a cns stimulant and bioactive food component with the molecular formula c8h10n4o2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 3g6a5w338e, chemically known as 1,3,7-trimethylxanthine but more generally known as caffeine, which bears u.s. national institutes of health compound identifier 2519. caffeine comes in many forms, including base, benzoate, benzoate sodium, bromide, citrate, hydrobromide, hydrochloride, hydroiodide, monohydrate, salicylate, sodium benzoate, sodium benzoicum, and sodium salicylate. the european medicines agency schedules caffeine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub13146mig. the third component of this combination drug is a histamine-1 receptor antagonist with the molecular formula c17h21no, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier k65lb6598j, chemically known as n,n-dimethyl-2-(alpha-phenyl-o-tolyloxy)ethylamine but more generally known as phenyltoloxamine, which bears u.s. national institutes of health compound identifier 7077. the european medicines agency schedules phenyltoloxamine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09791mig. the term phenyltoloxamine is an international non-proprietary name or inn (see world health organization inn reference publication, volume 13, no. 12, 1959, list 3). the fourth component of this combination drug is a nonsteroidal antiinflammatory drug, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier em8bm710zc. the european medicines agency schedules salicylamide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub10426mig. salicylamide generally arises in the molecular formula c7h7no2. the term salicylamide is an international non-proprietary name or inn.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. acetaminophen/caffeine/pyrilamine. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics. the first component of this combination drug is an analgesic and antipyretic with the molecular formula c8h9no2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 362o9itl9d, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears u.s. national institutes of health compound identifier 1983. acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. the european medicines agency schedules acetaminophen in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09611mig. the world health organization schedules acetaminophen in its anatomical therapeutic chemical (atc) classification. the second component of this combination drug is a cns stimulant and bioactive food component with the molecular formula c8h10n4o2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 3g6a5w338e, chemically known as 1,3,7-trimethylxanthine but more generally known as caffeine, which bears u.s. national institutes of health compound identifier 2519. caffeine comes in many forms, including base, benzoate, benzoate sodium, bromide, citrate, hydrobromide, hydrochloride, hydroiodide, monohydrate, salicylate, sodium benzoate, sodium benzoicum, and sodium salicylate. the european medicines agency schedules caffeine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub13146mig. the third component of this combination drug is a histamine-1 receptor antagonist with the molecular formula c17h23n3o, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier hpe317o9tl, chemically known as n,n-dimethyl-n-(p-methoxybenzyl)-n-(2-pyridyl)ethylenediamine but more generally known as pyrilamine, which bears u.s. national institutes of health compound identifier 4992.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. acetaminophen/caffeine/salicylamide. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics. the first component of this combination drug is an analgesic and antipyretic with the molecular formula c8h9no2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 362o9itl9d, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears u.s. national institutes of health compound identifier 1983. acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. the european medicines agency schedules acetaminophen in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09611mig. the world health organization schedules acetaminophen in its anatomical therapeutic chemical (atc) classification. the second component of this combination drug is a cns stimulant and bioactive food component with the molecular formula c8h10n4o2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 3g6a5w338e, chemically known as 1,3,7-trimethylxanthine but more generally known as caffeine, which bears u.s. national institutes of health compound identifier 2519. caffeine comes in many forms, including base, benzoate, benzoate sodium, bromide, citrate, hydrobromide, hydrochloride, hydroiodide, monohydrate, salicylate, sodium benzoate, sodium benzoicum, and sodium salicylate. the european medicines agency schedules caffeine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub13146mig. the third component of this combination drug is a nonsteroidal antiinflammatory drug, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier em8bm710zc. the european medicines agency schedules salicylamide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub10426mig. salicylamide generally arises in the molecular formula c7h7no2. the term salicylamide is an international non-proprietary name or inn.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. acetaminophen/calcium carbonate. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics. the first component of this combination drug is an analgesic and antipyretic with the molecular formula c8h9no2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 362o9itl9d, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears u.s. national institutes of health compound identifier 1983. acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. the european medicines agency schedules acetaminophen in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09611mig. the world health organization schedules acetaminophen in its anatomical therapeutic chemical (atc) classification. the second component of this combination drug a nutritional supplement with the molecular formula co3.ca, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier h0g9379fgk, chemically known as carbonic acid, calcium salt (1:1) but more generally known as calcium carbonate, which bears u.s. national institutes of health compound identifier 10112. the european medicines agency schedules calcium carbonate in its extended eudravigilance medicinal product dictionary or xevmpd under index sub13166mig. the world health organization schedules calcium carbonate in its anatomical therapeutic chemical (atc) classification.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. acetaminophen/calcium carbonate/magnesium carbonate/magnesium ox. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics. the first component of this combination drug is an analgesic and antipyretic with the molecular formula c8h9no2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 362o9itl9d, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears u.s. national institutes of health compound identifier 1983. acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. the european medicines agency schedules acetaminophen in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09611mig. the world health organization schedules acetaminophen in its anatomical therapeutic chemical (atc) classification. the second component of this combination drug is a nutritional supplement with the molecular formula co3.ca, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier h0g9379fgk, chemically known as carbonic acid, calcium salt (1:1) but more generally known as calcium carbonate, which bears u.s. national institutes of health compound identifier 10112. the european medicines agency schedules calcium carbonate in its extended eudravigilance medicinal product dictionary or xevmpd under index sub13166mig. the world health organization schedules calcium carbonate in its anatomical therapeutic chemical (atc) classification. the third component of this combination drug is an electrolyte replacement agent, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 0e53j927na. the european medicines agency schedules magnesia carbonica in its extended eudravigilance medicinal product dictionary or xevmpd under index sub34276. magnesium carbonate generally arises in the molecular formula co3.mg.h2o. the term magnesium carbonate is a united states homeopathic pharmacopoeia name designation. the fourth component of this combination drug is a nutritional supplement and laxative, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 3a3u0gi71g. the european medicines agency schedules magnesium oxide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub14436mig. magnesium oxide generally arises in the molecular formula mgo. the term magnesium oxide is a united states homeopathic pharmacopoeia name designation.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. acetaminophen/cinnamedrine/pamabrom. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf) which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics. the first component of this combination drug is an analgesic and antipyretic with the molecular formula c8h9no2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 362o9itl9d, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears u.s. national institutes of health compound identifier 1983. acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. the european medicines agency schedules acetaminophen in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09611mig. the world health organization schedules acetaminophen in its anatomical therapeutic chemical (atc) classification. the second component of this combination drug is an adrenergic agonist with the molecular formula c19h23no, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier y1245j8012, chemically known as benzenemethanol, alpha-(1-(methyl(3-phenyl-2-propenyl)amino)ethyl)- but more generally known as cinnamedrine, which bears u.s. national institutes of health compound identifier 5370611. the european medicines agency schedules cinnamedrine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06301mig. the term cinnamedrine is an international non-proprietary name or inn (see world health organization inn reference publication, volume 22, no. 10, 1968, list 8). the third component of this combination drug is a diuretic with the molecular formula c7h7brn4o2.c4h11no, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier ua8u0kjm72, chemically known as 8-bromo-3,7-dihydro-1,3-dimethyl-1h-purine-2,6-dione compound with 2-amino-2-methyl-1-propanol (1:1) but more generally known as pamabrom, which bears u.s. national institutes of health compound identifier 11806. the european medicines agency schedules pamabrom in its extended eudravigilance medicinal product dictionary or xevmpd under index sub14745mig.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. acetaminophen/pamabrom. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf) which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics. the first component of this combination drug is an analgesic and antipyretic with the molecular formula c8h9no2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 362o9itl9d, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears u.s. national institutes of health compound identifier 1983. acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. the european medicines agency schedules acetaminophen in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09611mig. the world health organization schedules acetaminophen in its anatomical therapeutic chemical (atc) classification. the second component of this combination drug is a diuretic with the molecular formula c7h7brn4o2.c4h11no, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier ua8u0kjm72, chemically known as 8-bromo-3,7-dihydro-1,3-dimethyl-1h-purine-2,6-dione compound with 2-amino-2-methyl-1-propanol (1:1) but more generally known as pamabrom, which bears u.s. national institutes of health compound identifier 11806. the european medicines agency schedules pamabrom in its extended eudravigilance medicinal product dictionary or xevmpd under index sub14745mig.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. acetaminophen/pamabrom/pyridoxine. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf) which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics. the first component of this combination drug is an analgesic and antipyretic with the molecular formula c8h9no2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 362o9itl9d, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears u.s. national institutes of health compound identifier 1983. acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. the european medicines agency schedules acetaminophen in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09611mig. the world health organization schedules acetaminophen in its anatomical therapeutic chemical (atc) classification. the second component of this combination drug is a diuretic with the molecular formula c7h7brn4o2.c4h11no, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier ua8u0kjm72, chemically known as 8-bromo-3,7-dihydro-1,3-dimethyl-1h-purine-2,6-dione compound with 2-amino-2-methyl-1-propanol (1:1) but more generally known as pamabrom, which bears u.s. national institutes of health compound identifier 11806. the european medicines agency schedules pamabrom in its extended eudravigilance medicinal product dictionary or xevmpd under index sub14745mig. the third component of this combination drug is a b vitamin with the molecular formula c8h11no3, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier kv2jz1bi6z, chemically known as 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol but more generally known as pyridoxine, which bears u.s. national institutes of health compound identifier 1054. the european medicines agency schedules pyridoxine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub10168mig. the term pyridoxine is an international non-proprietary name. the world health organization schedules pyridoxine in its anatomical therapeutic chemical (atc) classification.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. aspirin/caffeine. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. acetaminophen/phenobarbital. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf) which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics. the first component of this combination drug is an analgesic and antipyretic with the molecular formula c8h9no2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 362o9itl9d, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears u.s. national institutes of health compound identifier 1983. acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. the european medicines agency schedules acetaminophen in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09611mig. the world health organization schedules acetaminophen in its anatomical therapeutic chemical (atc) classification. the second component of this combination drug is a barbiturate and anticonvulsant agent with the molecular formula c12h12n2o3, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier yqe403bp4d, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-ethyl-5-phenyl- but more generally known as phenobarbital, which bears u.s. national institutes of health compound identifier 4763. the european medicines agency schedules phenobarbital in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09770mig. the term phenobarbital is an international non-proprietary name or inn (see world health organization inn reference publication, volume 13, no. 12, 1959, list 3). the world health organization schedules phenobarbital in its anatomical therapeutic chemical (atc) classification.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. acetaminophen/pyrilamine maleate. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf) which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics. the first component of this combination drug is an analgesic and antipyretic with the molecular formula c8h9no2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 362o9itl9d, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears u.s. national institutes of health compound identifier 1983. acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. the european medicines agency schedules acetaminophen in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09611mig. the world health organization schedules acetaminophen in its anatomical therapeutic chemical (atc) classification. the second component of this combination drug is the fifth component of this combination drug is a histamine-1 receptor antagonist with the molecular formula c17h23n3o, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier hpe317o9tl, chemically known as n,n-dimethyl-n-(p-methoxybenzyl)-n-(2-pyridyl)ethylenediamine but more generally known as pyrilamine, which bears u.s. national institutes of health compound identifier 4992.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. acetaminophen/salicylamide. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf) which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics. the first component of this combination drug is an analgesic and antipyretic with the molecular formula c8h9no2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 362o9itl9d, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears u.s. national institutes of health compound identifier 1983. acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. the european medicines agency schedules acetaminophen in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09611mig. the world health organization schedules acetaminophen in its anatomical therapeutic chemical (atc) classification. the second component of this combination drug is a nonsteroidal antiinflammatory drug, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier em8bm710zc. the european medicines agency schedules salicylamide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub10426mig. salicylamide generally arises in the molecular formula c7h7no2. the term salicylamide is an international non-proprietary name or inn.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. acetaminophen/tramadol. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf) which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics. the first component of this combination drug is an analgesic and antipyretic with the molecular formula c8h9no2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 362o9itl9d, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears u.s. national institutes of health compound identifier 1983. acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. the european medicines agency schedules acetaminophen in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09611mig. the world health organization schedules acetaminophen in its anatomical therapeutic chemical (atc) classification. the second component of this combination drug is an analgesic agent with the molecular formula c16h25no2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 39j1lgj30j, chemically known as cyclohexanol, 2-((dimethylamino)methyl)-1-(m-methoxyphenyl)- but more generally known as tramadol, which bears u.s. national institutes of health compound identifier 33741. the european medicines agency schedules tramadol in its extended eudravigilance medicinal product dictionary or xevmpd under index sub11210mig. the term tramadol is an international non-proprietary name or inn (see world health organization inn reference publication, volume 28, no. 10 1974, list 14). the world health organization schedules tramadol in its anatomical therapeutic chemical (atc) classification.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. aluminum hydroxide/aspirin/calcium carbonate/magnesium hydroxide. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. aluminum hydroxide/aspirin/magnesium hydroxide. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. aspirin/butalbital. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. aspirin/butalbital/caffeine. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. aspirin/butalbital/caffeine/phenacetin. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. aspirin/meprobamate. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. aspirin/caffeine/cinnamedrine. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. aspirin/caffeine/gelsemium/hyoscyamus. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. aspirin/caffeine/salicylamide. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. aspirin/calcium carbonate/magnesium carbonate/magnesium oxide. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. aspirin/dihydroxyaluminum aminoacetate. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. aspirin/dihydroxyaluminum aminoacetate/magnesium carbonate. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. aspirin/ethoheptazine/meprobamate. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. aspirin/magnesium carbonate. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. aspirin/magnesium oxide. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. caffeine/phenacetin/salicylamide/styramate. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. calcium/ergocalciferol/salicylamide. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics.. "
"combination non-opioid analgesics. this classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term non-opioid analgesics. typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.. choline salicylate/magnesium salicylate. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class cn103. this va drug class (cn103) classifies this compound as belonging to the group non-opioid analgesics.. "
"combination volume expanders. this classification denotes combination drugs and preparations which liquid used to replace blood plasma, usually a saline solution, often with serum albumins, typically to treat dehydration, and these replace blood volume, hence the term volume expanders. typical combination volume expanders constituents are dextran 40, dextran 70, dextran 75, and hetastarch.. . "
"combination volume expanders. this classification denotes combination drugs and preparations which liquid used to replace blood plasma, usually a saline solution, often with serum albumins, typically to treat dehydration, and these replace blood volume, hence the term volume expanders. typical combination volume expanders constituents are dextran 40, dextran 70, dextran 75, and hetastarch.. dextran 40/sodium chloride. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class bl800. this va drug class (bl800) classifies this compound as belonging to the group volume expanders.. "
"combination volume expanders. this classification denotes combination drugs and preparations which liquid used to replace blood plasma, usually a saline solution, often with serum albumins, typically to treat dehydration, and these replace blood volume, hence the term volume expanders. typical combination volume expanders constituents are dextran 40, dextran 70, dextran 75, and hetastarch.. dextran 70/dextrose. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class bl800. this va drug class (bl800) classifies this compound as belonging to the group volume expanders.. "
"combination volume expanders. this classification denotes combination drugs and preparations which liquid used to replace blood plasma, usually a saline solution, often with serum albumins, typically to treat dehydration, and these replace blood volume, hence the term volume expanders. typical combination volume expanders constituents are dextran 40, dextran 70, dextran 75, and hetastarch.. dextran 70/sodium chloride. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class bl800. this va drug class (bl800) classifies this compound as belonging to the group volume expanders.. "
"combination volume expanders. this classification denotes combination drugs and preparations which liquid used to replace blood plasma, usually a saline solution, often with serum albumins, typically to treat dehydration, and these replace blood volume, hence the term volume expanders. typical combination volume expanders constituents are dextran 40, dextran 70, dextran 75, and hetastarch.. dextran 75/sodium chloride. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class bl800. this va drug class (bl800) classifies this compound as belonging to the group volume expanders.. "
"combination volume expanders. this classification denotes combination drugs and preparations which liquid used to replace blood plasma, usually a saline solution, often with serum albumins, typically to treat dehydration, and these replace blood volume, hence the term volume expanders. typical combination volume expanders constituents are dextran 40, dextran 70, dextran 75, and hetastarch.. hetastarch/electrolytes. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class bl800. this va drug class (bl800) classifies this compound as belonging to the group volume expanders.. "
"combination volume expanders. this classification denotes combination drugs and preparations which liquid used to replace blood plasma, usually a saline solution, often with serum albumins, typically to treat dehydration, and these replace blood volume, hence the term volume expanders. typical combination volume expanders constituents are dextran 40, dextran 70, dextran 75, and hetastarch.. hetastarch/sodium chloride. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class bl800. this va drug class (bl800) classifies this compound as belonging to the group volume expanders.. "
